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Abstract 
The objective of this project is to develop patient dose-response models and to 
provide an adequate drug administration regimen for anaesthesia to avoid under- or 
over-dosing of patients. The controllers are designed to compensate for patients’ 
inherent drug response variability, to achieve the best output disturbance rejection, 
and to maintain optimal set point response.   
 
To address this issue, this project uses four independent methods to investigate the 
control strategies for the regulation of hypnosis. Two medications are used in a 
thorough evaluation and comparison of controller performance.  
 
A robust internal model controller (RIMC) based on the Bispectral Index (BIS) is 
investigated firstly.  The  controller  compares  the  measured  BIS  with  its  input  
reference  to  provide  the expected  Propofol  concentration,  and  then  the  
controller  manipulates  the  anaesthetic  Propofol concentration  entering  the  
anaesthetic  system  to  achieve  the  desired  BIS  value.  This study also develops 
patient dose-response models. The performance of the RIMC is comprehensively 
compared with that of proportional-integral-derivative (PID) controller for the 
robustness, set-point changes, disturbances and noise in the measured BIS. 
Numerical simulations illustrate that the RIMC performed better than the PID 
controller. The robust performance of the two controllers is evaluated for a wide 
range of patient models by varying in patient parameters. 
 
The impact of the time-delays of patient and instrumentation on a closed-loop depth 
of anaesthesia control system was investigated. In this study, the Smith predictive 
   iii 
technique is used to identify and compensate for the time-delay problem and improve 
the overall response of the depth of anaesthesia. The proposed method is validated 
using measured BIS signals in simulation. The results showed that the proposed 
procedure improves the performance of the closed-loop system for reference tracking 
and overall stability. The proposed method also has approximately 15% less 
overshoot, a two minute shorter settling time, and is more robust to disturbance 
rejection. 
 
The problem of non-linearity is identified in the depth of anaesthesia model and a 
deadbeat controller is designed in response to this problem. The proposed system is 
evaluated in simulation using Matlab and Simulink, and results are compared with a 
traditional PID control system and with an internal model control (IMC) controller. 
The results show that the proposed scheme has less over- and under-shoot, shorter 
settling time and is more robust to depth of anaesthesia disturbances. In addition, the 
proposed method is easy to implement. 
 
The Model Predictive Control (MPC) technique is also investigated in depth of 
Anaesthesia (DoA) control. The proposed robust control system with a predictive 
controller is evaluated in simulation. The result is compared with two control 
systems. First compared with a conventional PID controller and then with a control 
system with an Internal Model Controller. The results show that the proposed scheme 
has a smaller overshoot (by about 10%) and a shorter settling time (by about 2 
minutes shorter) and is more robust to disturbances caused by parameter changes. 
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CHAPTER 1  
 
INTRODUCTION 
 
 
1.1 Anaesthesia and Regulation in Operation Theatres 
During surgery general anaesthesia renders a patient unconscious and without pain or 
memory. Anaesthesia professionals may use three medications: hypnotic drugs to 
numb the brain so the patient will be asleep and will not remember the surgery, 
analgesic drugs to prevent pain, and paralytics to keep the patient still when surgeon 
is working. Knowing the exact amount of each medication a patient requires present 
a great challenge because each person has individual needs and these needs change 
during surgery. If too little hypnotic is given, the patient is at risk of anaesthesia 
awareness or unexpected awaking. If too little analgesic is given, the patient may 
also experience pain during surgery. Some of these patients will be aware and feel 
pain but be unable to move or speak. More commonly, too much anaesthesia may be 
given which can prolong the waking period or increase other side effects. Table 1.1 
shows the incidence of awareness. In other words, there are still a large number of 
patients who remain awake during surgery due to lack of anaesthetise (Bruhn et al. 
2006). 
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Table 1.1: Incidence of awareness during surgery (Bruhn et al. 2006). 
Author Year Sample Awareness 
Hutchinson 1960 656 1.2 
Harris 1971 120 1.6 
McKenna 1973 200 1.5 
Wilson 1975 490 0.8 
Liu et al 1990 1000 0.2 
Sandin 1997-1998 11785 0.15 
Myles 1993-2000 10811 0.11 
Sebel 2001-2002 19575 0.13 
Ekman et al 2003 7826 0.18 
Lennmarken& Sandin 2004 1238 0.9 
Rungreungvanick 2005 150000 0.07 
 
 
Brain monitors, such as the Bispectral Index monitor, can now be used to measure a 
patient’s brain response to anaesthesia. This information helps clinicians to adjust the 
amount of medication to improve recovery from anaesthesia; and it also helps 
clinicians to reduce the risk of patient awareness (Downey & Seagrave 2000; Foster, 
Bojak & Liley 2008; Furutani et al. 2010; Gaohua, Maekawa & Kimura 2006; Glass 
et al. 1997). 
 
Currently, anaesthesia is one of the safest components of any operations. In 1986, a 
survey (Spence 1988) revealed that the overall death rate attributable directly to 
anaesthetic medications was 1:185,056, as shown in Table 1.2 (Brown 1992). Of the 
approximately 28 million patients undergoing anaesthesia and surgery in the United 
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States, it is estimated that about 150 patients die each year from difficulties and 
complications due to anaesthesia (Wiklund & Rosenbaum 1997). 
 
Table 1.2: Contemporary anaesthetic mortality rates adapted from (Brown 1992) 
Study 
 
Year Total Cases Mortality Rate 
 
Beecher 
Clifton 
Harrison 
Hatton 
Lunn 
Eichhorn 
 
 
1948-1952 
1952-1962 
1967-1976 
1977 
1979 
1976-1985 
 
599,548 
205,640 
240,483 
190,380 
1,147,362 
757,000 
 
1:1,560 
a 
1:3,955 
a
 
1:4,537 
b
 
1:2,885 
a
 
1:6,789 
e
 
1:151,400 
d
 
 
Eichhorn 
CEPOD 
CEPOD 
 
 
1985-1988 
1986 
1986 
 
244,000 
486,000 
486,000 
 
0 
d
 
1:185,056 
e
 
1:185 
c
 
 
a: All operation cases considered in calculation 
b: Cases included if death occurred in less than 24 hours 
c: Cases included if some contribution by anaesthetic 
d: Only ASA physical status I and II patients included 
e: Only deaths directly attributable to anaesthetic included 
CEPOD: Confidential Enquiry into Postoperative Deaths 
 
Depth of anaesthesia (DoA) can be defined as the lack of response and recall to 
noxious stimuli. The anaesthetic management of a surgical patient is a process that 
relies on the experience of an anaesthetist as there are currently no direct means of 
assessing a patient’s level of consciousness during surgery. The decision for the 
initial anaesthetic level is generally made using the recommended drug dosages 
based on different patient characteristics, such as age and weight (Lemos et al. 2006). 
The anaesthetist determines any subsequent alteration in the anaesthetic level by 
observing physical signs from the patient (McAnulty, Robertshaw & Hall 2000). 
These physical signs, the indirect indicators of the depth of anaesthesia, may include 
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changes in blood pressures or heart rate, lacrimation (the production of tears in the 
eyes), facial grimacing, muscular movements, spontaneous breathing, diaphoresis 
(sweating, especially sweating induced for medical reasons), and other signs that 
may predicate awareness. 
 
However, they are not reliable indicators of changes in patients’ levels of 
consciousness. Although an anaesthetist can adjust recommended anaesthetic 
dosages based on individual patient characteristics, these adjustments cannot always 
account for variability in patient responses to anaesthesia or changes in anaesthetic 
requirements during the course of surgery (Bruhn 1999). 
 
Anaesthetic under-dosing can cause intra-operative awareness, and explicit 
cognizance, resulting in postoperative psychological consequences. The need for a 
reliable technique for controlling the anaesthetic titration has prompted anaesthetists 
to overdose in order to prevent possible intra-operative awareness. However, 
anaesthetic overdosing prolongs the recovery period, which increases healthcare 
costs and the utilization of post-recovery care.  
1.2 Depth of Anaesthesia Control and Monitoring  
The major difficulty in the design of automatic controllers for anaesthesia is the 
inherent patient variability due to differences in demographics and drug tolerance 
(Saldien, Vermeyen & Wuyts 2003). These discrepancies have been translated into 
the pharmacokinetics-pharmacodynamics (PKPDs) dose-response model uncertainty 
that may affect the stability of the closed loop system. A controller is considered to 
be robust if it is insensitive to the differences between the actual patient’s drug-
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response and the nominal model for which the controller was designed (Dumont, 
Martinez & Ansermino 2009). 
 
The potent agents used in the practice of anaesthesia have narrow therapeutic 
margins, so accurate control of anaesthesia is of utmost importance. The significance 
of a robust controller is to provide an adequate drug administration regimen for the 
anaesthesia to avoid the under-or over-dosing of patients. The controller is designed 
to compensate for patients’ inherent drug response variability, to achieve better 
disturbance rejection, and to attain good set point response. 
 
In the past, anaesthetists relied solely on clinical signs to assess the depth of 
anaesthesia because of the lack of a single widely accepted indicator for anaesthetic 
adequacy. Nowadays there are a number of monitoring tools available to quantify the 
EEG, in order to derive a surrogate measurement of hypnosis (Kissin 2000). 
 
Snow (1847) first used clinical signs such as breathing patterns, eyeball movements 
and the inhibition of intercostal muscles to describe five degrees of narcotism for 
ether anaesthesia. Guedel (1920) discovered four stages of ether by using somatic 
muscle tone, respiratory patterns and ocular signs. These methods have been proven 
not to provide a dependable guide for depth of anaesthesia assessment while using 
multiple types of anaesthetics. Heart rate (HR), and mean arterial pressure (MAP), 
are also regularly used to monitor patient status. Ghouri et al. showed that 
hemodynamic responses (HR and MAP) could be attributed to several factors 
(Ghouri, Monk & White 1993). However, measurements of these quantities do not 
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give a satisfactory indication of the level of drugs required, and further indicators 
must be considered.  
 
More recently, Bispectral Index (BIS) monitoring systems have been gaining clinical 
approval as a strong indicator of anaesthetic depth with respect to a variety of 
anaesthetics (Rosow & Manberg 2001). In general, BIS monitor allows anaesthesia 
professionals to access processed EEG information (Kreuer et al. 2001) as a measure 
of the effect of certain anaesthetics on patients (Glass et al. 1997). The clinical 
impact of BIS monitoring has been demonstrated in a variety of randomized 
controlled trials, these trials have revealed the potential for BIS monitoring to 
facilitate improvements in patient safety during anaesthesia care (Struys et al. 2004; 
Struys et al. 2003). The range of BIS values are stated in Table.1.3 (Drummond 
2000). 
 
Table 1.3: BIS values and associated hypnotic states (Drummond 2000). 
BIS value 
 
Hypnotic state 
0 Depressed EEG 
20 Profound anaesthetic level 
40 Deep hypnotic level 
60 Moderate hypnotic level 
80 Sedated 
100 Awake 
 
 
The BIS is scaled between 0 and 100. A value of 100 represents the conscious state. 
With increasing concentration of anaesthetics, the index decreases (Hui-Hing, Beck 
& Bloom 2004). During general anaesthesia the index sits between 60 and 40, as 
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shown in Figure 1.1. Lower values represent deep hypnotic states, while values 
between 90 and 60 usually represent sedation levels (Bibian 2006). 
 
Low Probability of 
Explicit Recall
100
80
20
40
60
0
BIS
Awake
Light / Moderate 
Sedation
Deep Sedation
General Anaesthesia 
Deep Hypnosis
Increasing Burst 
Suppression
Isoelectric EEG
Memory Intact
Low Probability of 
Consciousness
Memory Function
Lost
Light Hypnotic 
State
Moderate Hypnotic 
State
Deep Hypnotic 
State
 
Figure 1.1: Bispectral Index Scale and its meaning (Zikov et al. 2002) 
 
1.3 Patient Model and Hypotheses for DoA Control 
The design of a robust controller for automating anaesthesia requires a reliable 
mathematical model to represent anaesthesia (hypnotic, paralytic and analgesic) 
dynamics, as well appropriate hardware devices to calculate and monitor the depth of 
anaesthesia.  The mathematical model should precisely represents the relationship 
between the administered anaesthetic amount and its effect on the patient in terms of 
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hypnosis, paralysis and analgesia (Yelneedi, Samavedham & Rangaiah 2009). 
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling is the route of 
constructing mathematical model for the time course of dose to concentration 
(pharmacokinetics) and concentration to effect (pharmacodynamics) (Minto, & 
Schnider, 2008). Intravenous anaesthesia is concerned with the use of intravenous 
drugs to attain the desired effects throughout the induction of anaesthesia during 
surgery, and in the early postoperative period (Masui et al. 2009). The major 
medication classes used for enhancing general anaesthesia during surgery are the 
hypnotics, the analgesics, and the paralytics (Homer & Stanski 1985). These have 
given a guarantee of unconsciousness and the smooth progress of endotracheal 
intubation, which provides analgesia, and suppresses the hemodynamic and 
neuroendocrine responses to surgery (Homer & Stanski 1985; Manyam et al. 2006; 
Minto et al. 1997; Muñoz et al. 2004). 
 
The main objectives are that the patient should speedily lose consciousness and 
experience no consciousness during the operation. The level of analgesia should 
closely follow the level of surgical stimulation to ensure hemo-dynamic stability; the 
medication effects should rapidly wear off at the end of the surgery so that the patient 
has no residual sedation, no residual muscle paralysis, and, ideally, no respiratory 
depression and no painful sensation from the surgery of trauma (Vanluchene et al. 
2004). 
 
This study of pharmacokinetics is particularly interested in compartmental (three-
compartment models), the effect-site concept (characterized by the rate constant 
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   ), and the Hill equation (which defines the concentration–effect relationship) as 
shown in Figure 1.2 and Figure1.3 (Bailey & Haddad 2005). 
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Figure 1.2: Pharmacokinetic-pharmacodynamic models 
 
In contrast to anaesthesia, which involves the administration of most of the 
medications by intravenous bolus or infusion for procedures lasting minutes to hours, 
many other specialties involve the administration of drugs by repeated oral dosing 
for conditions lasting weeks, months, or years. Anaesthesia relies increasingly on 
drugs with a very rapid onset of effect (1–2 min), whereas in some medical 
specialties the onset time is measured in weeks (Minto, & Schnider, 2008; Mourisse 
et al. 2007; Munson & Bowers 1967; Nunes, & Mendonça 2005). As a result, many 
pharmacokinetics and pharmacodynamics studies make up the anaesthesia literature. 
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Figure 1.3: Effect-site concentrations (ng/ml) 
 
A combination of anaesthetics, with or without neuro-muscular blocking (NMB), are 
administered together to create the state of general anaesthesia.  These medications, 
even, when taken within the same family, have different properties. Since  they  
provide  the  actuators  through  which  the patient's  state  can be  regulated  (i.e.,  
allowing  the control  of the  anaesthetic  state),  it is necessary  to  provide  control  
engineers  with  some  knowledge  of the mechanisms of action of the most  
commonly used  drugs (Bibian 2006). 
 
Inhaled anaesthetics:    With the advent of fluorine technology in the 1940s, new 
inhaled anaesthetics were developed.  Compared to ether and chloroform, fluorine 
compounds have lower blood solubility (thus ensuing rapid induction and recovery), 
lower toxicity, are less irritating to the airway, and are not flammable. Nowadays 
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three agents are commonly used with or without nitrous oxide:  isoflurane, desflurane 
and sevoflurane. All   these agents provoke a decrease in mean arterial blood 
pressure when administered to healthy subjects. 
Intravenous anaesthetics:    Intravenous  anaesthetics  can be classified into five 
families:  Barbiturates  (thiopental),     Benzodiazepines (midazolam, diazepam,  
lorazepam),  Phencyclidines (ketamine),  Carboxylated imidazoles  (etomidate),  and 
Isopropylphenols  (propofol).  Compared with volatile agents, intravenous 
anesthetics (besides ketamine) do not provide analgesic effects-hence, they are 
defined as hypnotic rather   than anaesthetic drugs.   However, opioids and 
intravenous anaesthetics, when used in combination, are strongly synergistic both in 
terms of hypnosis and in terms of analgesia. Propofol has introduced in the early 
1990s and has become the intravenous drug of choice in anaesthesia. Two particular 
characteristics of propofol are its fast redistribution and its metabolism.  As a result it 
can be  easily used  in  infusion  schemes  as it provides very fast  emergence,  
without  cumulative  effect. 
Neuromuscular blockade (NMB): NMB medication blocks the transmission of 
nerve impulses at the neuromuscular connection, and paralysis the skeletal muscles. 
Mechanical ventilation should be given to maintain sufficient respiration, because 
NMB also paralysis the muscles required for breathing. These treatments are used 
together with hypnotics and/or analgesics to create skeletal muscle relaxation and 
facilitate intubation of the trachea and to give optimal surgical conditions. May 
sometimes NMB causes transient hypotension but does not have any hypnotic or 
analgesic properties. In addition, these do not work together, in a clinically 
significant way, with anaesthetics and opioids. When a longer effect is required 
NMB types such as Vecuronium, Mivacurium and Rocuronium are normally used 
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(Sreenivas, Lakshminarayanan & Rangaiah 2007). With the introduction of NMB 
medications in the early 1940, the risk of incomplete paralusis vanished. A growing 
number of intra-operative cases related to the use of NMB were reported. 
 
The hypotheses to be addressed in this PhD thesis are: 
 
1. Robust model based predictive control strategies can be developed to control 
nonlinear systems with input and state constraints to give nearest time 
optimal control. 
2. These strategies will give improved or better performance than the existing 
strategies that consider input and state constraints. 
3. Set point changes are often made during the surgical procedure. The 
controller should completely respond to these changes without any delay. In 
addition, disturbances occur during the operation depending on the strength 
of the surgical stimulus. The designed controller should guarantee the 
required anesthetic depth in the patient in spite of these disturbances. 
4. Drug delivery constraints and the maximum amount of drug infused are most 
important for patient safety and these constraints should be explicitly 
included in the designed closed-loop feedback controller algorithm. 
1.4 Research Objectives 
The aim of this dissertation is to construct and develop accurate feedback control of 
DoA, and a reliable mathematical model for model base predictive control of DoA. 
The research also compares performance of MBPC strategies with conventional 
control methods such as PID controllers for DoA. It also analyses and develops the 
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strategies to ensure the robustness and stability of the system in the presence of 
nonlinearities such as parameter variations, disturbance rejection, noise suppression 
etc. 
 
The mathematical model employed in recent studies on depth of anaesthesia control 
is a series combination of a linear PK model and a nonlinear PD model. A theoretical 
effect compartment is also attached to the central compartment to represent the time-
lag between observed effect and central (plasma) concentration. The parameters used 
in the PK and PD models are the population mean values and the “patients” would 
have parameters that are different from the nominal values used in the controller 
design. The PK model parameters can be estimated approximately through covariate 
adjustments of weight, age, and sex, but it is impossible to estimate the PD 
parameters. Therefore, the designed controller should be robust and result in stable 
responses for all patients characterized by a range of PD parameters. 
 
The following specific objectives are formulated to achieve the research aim. The 
objectives are to apply and evaluate the promising MBPC and IMC approaches for 
DoA regulation using the Bispectral Index as the controlled variable, to manipulate 
propofol (a new intravenous anaesthetic) infusion and also to verify DoA models via 
simulation and model validation methods. 
 
This research will result in the publications of predictive control algorithms for 
nonlinear systems with input and state constraints. These algorithms will deliver a 
performance superior to any other contemporary control algorithms. The stability and 
robustness analysis will ensure that the system stays stable and can withstand 
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parameter variations and disturbances. The new control methods can be used to 
control multivariable structures and will be very useful in the control of nonlinear 
systems, in particular DoA.  
 
An automatic controller that infuses drugs based on the patient’s anaesthetic level 
will provide the following benefits:  
 
1. It will reduce the anaesthetist’s workload during the surgery and allow 
him/her to monitor and deal with other critical aspects of the surgery (blood 
loss, sudden blood pressure change, etc.). 
2. Better depth of anaesthesia will be achieved compared to manual 
administration because the controller variable is sampled more frequently 
leading to active adjustment of the delivery rate of the drug. 
3. A well-designed automatic control system can tailor the drug dosage based on 
the patient’s response, which avoids both over-dosage and under-dosage of 
the drugs. Overall, these improve the patient’s rehabilitation and safety 
during and after the surgery. 
1.5 Structure of Dissertation 
This dissertation contains eight chapters addressing the importance of the processes 
involved in depth of anaesthesia control and a detailed description of the scope of the 
present work. The structure of the dissertation is given below: 
 
Chapter 1 introduces the objectives of the dissertation and gives an introduction of 
the features of depth of anaesthesia, input, controller, modelling, and output. This 
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chapter introduces anaesthesia regulation, and then mathematical model structure, 
anaesthetics, depth of anaesthesia monitoring, research hypotheses. A short 
discussion of depth of anaesthesia is presented to give the reader with basic 
background material. 
 
Chapter 2 presents an extensive review of the various control strategies applied in 
clinical anaesthesia. This chapter also provides a complete overview of the modeling 
that is generally used in anaesthesia. In addition, some detailed control techniques for 
depth of anaesthesia is introduced. 
 
Chapter 3 focuses on human body mathematical models and the medication delivery 
system. This chapter provides the effect of the time dealy on depth of anaesthesia 
response. It also describes intra and inter-patient uncertainties in human body model. 
 
Chapter 4 investigates the internal model control technique in DoA. The first part 
focuses on the theoretical concepts of the depth of anaesthesia model and describes 
the internal model control. The second part of this chapter details the experimental 
and simulation work and discusses the results. This chapter covered three main 
elements: 
 
1. The theoretical considerations are used to give a fundamental 
understanding of the patient mathematical model of depth of anaesthesia. 
2. The experimental and simulation work includes a detailed explanation of 
the internal model control in Matlab and Simulink. 
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3. The last part of this chapter analyses the simulation results and compares 
the results with the performances of a PID controller. 
 
Chapter 5 addresses a closed-loop depth of anaesthesia control system, which 
applies Smith Predictive Technique to identify and compensate the problem caused 
by time-delay. This   chapter   also includes   the description of a human body model 
used in this study. This chapter coveres three main elements: 
 
1. The overall time-delay can be considered into two parts. The first is 
from the instrumentation parts, representing the time-delay at the 
instrument devices. The second is related to the dynamic response of 
the patient time-delay. 
2. The Smith Predictor Controller structure and the compensation of the 
time-delay.  
3. The simulation and results using real data are then analysed and 
verified. 
 
Chapter 6 investigates a PID-based robust deadbeat control technique in DoA 
control and proposes an application of the robust deadbeat technique to this system. 
This chapter comprises three main elements: 
 
1. Consideration of the drug modeling and the distribution of the drug 
administered within the body, which leads to a pharmacokinetic and 
pharmacodynamic modeling and the prediction of the blood plasma 
concentration of the drug. 
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2. The basic structure of the robust deadbeat control system, the deadbeat 
controller coefficients, response times, the deadbeat controller design and 
derivation. 
3. The robust deadbeat controller design for the depth of anaesthesia.  
 
Chapter 7 describes the control of hypnosis using model predictive controller 
(MPC). The first part focuses on non-linear model predictive control to find the 
future optimal anaesthetic infusion sequence in order to minimize the desired output 
trajectory over a prediction horizon. The second part of this chapter details the 
simulation work as well analysing the results. This chapter coveres the following 
work: 
1. A description of model predictive control technique, which focuses on the 
structure of the model predictive control. 
2.  A consideration of model predictive control design, which includes 
details of the constraints and the time horizons for depth of anaesthesia. 
3. An analysis and evaluation of the simulation results. 
 
Chapter 8 concludes the thesis and suggests further work. 
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CHAPTER 2  
 
LITERATURE REVIEW  
 
 
2.1 Background 
The aim of this chapter is to introduce the problems related to the mathematical 
models employed in DoA feedback control. It also addresses the significance of this 
research. 
 
A major gain of continuous intravenous drug infusion for general anaesthesia is the 
possibility of keeping a constant value of the effect concentration of the drug in use 
(Jensen et al. 2006). For DoA control the input, output, patient model and controller 
must be considered. Alonso et al. (2008) presented a method of target controlled 
infusion for neuromuscular blockade level of patients undergoing general 
anaesthesia. The estimates of the PK-PD model parameters are computed from data 
collected in the first 10 minutes, after a bolus is applied to the patient in the induction 
phase of anaesthesia (Alonso, Lemos & Mendonca 2008). Ionescu et al. (2008) 
presented a single-input (Propofol) single-output (Bispectral Index, BIS) model of a 
patient. The aim of the controller is to guarantee the stability in a desired range 
(Ionescu, et al. 2008). Absalom et al. produced a closed-loop control system of 
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anaesthesia that uses the BIS as the control variable to control the target blood 
concentration of the Propofol Target Controlled Infusion (TCI) system. The system 
was able to provide clinically sufficient anaesthesia in all patients, with enhanced 
accuracy of control. There was a tendency for more accurate control in those patients 
in whom the control algorithm incorporated effect-site steering (Absalom, & Kenny 
2003). An algorithm was proposed for controlling the effect site concentration using 
a TCI method. The method limits the peak plasma concentration, thereby slowing the 
start of anaesthetic drug effect but potentially improving side effects. Simulation was 
used to observe the delay in time to peak effect for five types of anaesthetic drugs 
when the peak plasma concentration was limited by the algorithm (Van Poucke, 
Bravo & Shafer 2004). The control system was evaluated in 30 patient’s cases. This 
study clearly suggests the desirability of individual tuning of the controller 
parameters. 
 
2.2 Feedback Control of Anaesthesia 
Feedback control of anaesthesia improves the quality of patient care at the same time 
reducing the administration and cost of anaesthetic medications. A method was 
presented by Mendonca & Lago (1998) for an enhanced tuning of the PID controller 
parameters to the patient’s individual dynamics (Mendonca & Lago 1998). Auditory 
Evoked Potentials (AEP) has been reported to satisfy many requirements for 
measurement the level of anaesthesia. The AEP has been shown to provide good 
discrimination of the conversion from asleep to aware and vice versa. This system 
has been developed to obtain a single index which presents the morphology of the 
AEP and the index has been used as the input signal for closed-loop anaesthesia 
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during surgery in patients who did not receive neuromuscular blocking drugs (Kenny 
& Mantzaridis 1999).  
 
In recent years, there have been increasing reports on DoA control using fuzzy. This 
is because it is a simple and effective technique for controlling non-linear and 
uncertain processes, and for dealing with imprecise, qualitative terms such as ‘‘low’’, 
‘‘medium’’, or ‘‘high’’, rather than precise measurements. Fuzzy rules are a core 
element and have more effects than other elements in a fuzzy system because they 
dominate the primary performance. However, the derivation of fuzzy rules is a 
common bottleneck in the application of fuzzy control (Nunes et al. 2005). For 
classifying DoA and model patients’ vital signs, Nunes et al (2005) developed a 
fuzzy relational classifier to classify a set of wavelet-extracted features from the AEP 
into different levels of DoA. They also developed a hybrid patient model using 
Takagi-Sugeno Kang fuzzy models (Nunes et al. 2005). 
 
Chuang et al. (2009) provided two rule bases to control the administration of 
Cisatracurium, a non-depolarizing neuromuscular blocking agent. One rule base is 
extracted from the objective approach of the Fuzzy Modelling Algorithm (FMA), 
and another is from the subjective approach of expert’s clinical experience. Shieh et 
al. (2006) defined evidence based on an adaptive genetic fuzzy clustering algorithm. 
A derived fuzzy knowledge model was proposed for quantitatively estimating the 
systolic arterial pressure (SAP), heart rate (HR), and Bispectral Index (BIS) using 12 
patients. A hierarchical system has been developed to provide on-line advice on the 
concentration of inhaled volatile anaesthetics for depth of anaesthesia control. It 
merges on-line measurements (such as systolic arterial pressure and heart rate) and 
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clinical information (such as sweating, lacrimation and movement) using hierarchical 
architecture and self-organizing fuzzy logic for reasoning (Shieh, J. S., Linkens & 
Asbury 2005). In this study a computer screen-based simulator was developed to 
simulate the administration of intravenous and analgesic drugs. It merged on-line 
measurements (such as systolic arterial pressure (SAP) and heart rate (HR)) and non-
numerical clinical signs (such as sweating, lacrimation and pupil response), using 
anaesthetists’ experience or self-organizing fuzzy logic control (SOFLC) algorithms 
to administer drugs into a patient. 
 
Voss et al.  (1987) developed an adaptive algorithm to control multi-input/multi-
output physiological systems and this method has been implemented and tested. The 
algorithm is a self-tuning controller that determines the input based on the expected 
difference between the actual output and desired output at a time interval equal to or 
greater than the system dead time. The algorithm was used to simultaneously control 
mean arterial pressure and cardiac output (CO) in anesthetized dogs by the 
simultaneous computer-controlled infusion of sodium nitroprusside and dobutamine. 
The results demonstrated the feasibility of using a advance moving average 
controller for multivariable drug delivery, but they also indicated the need for further 
work before clinical applications are attempted (Voss, Katona & Chizeck 1987). 
 
Asteroth et al. (1997) established the feasibility of different real-valued 
reinforcement learning approaches for the task of multivariate adaptive control in 
anaesthesia. They also defined and explored the appropriateness of reinforcement 
learning systems for automation in anaesthesia (Asteroth, Moller & Schwilden 
1997). Haddad et al. (2006) developed a direct adaptive control framework for 
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nonlinear uncertain nonnegative and compartmental systems with nonnegative 
control inputs. The framework was developed Lyapunov-based and guarantees 
partial asymptotic set-point regulation, that is, asymptotic set-point regulation with 
respect to that part of the closed-loop system states associated with the plant. A 
numerical example involving the infusion of the anaesthetic drug Propofol for 
maintaining a desired constant level of consciousness for non-cardiac surgery has 
also been provided to demonstrate the implementation of the proposed approach  
(Haddad, Hayakawa & Bailey 2006). The aim of the controllers is to supply an 
adequate drug administration treatment for Propofol to evade under or over dosing of 
the patients. These controllers aim to compensate for the patient’s inherent drug 
response variability, to accomplish good output disturbance rejection, and to achieve 
good tracking to set point response (Dumont, Martinez & Ansermino 2009). 
 
Janda et al. (2011) developed a closed-loop system to control the DoA and 
Neuromuscular Block (NMB) via the Bispectral Index and the Electromyogram 
(EMG) simultaneously, and evaluated the clinical performance of this combined 
system for general anaesthesia. The simultaneous closed-loop system using Propofol 
and Mivacurium was able to maintain the target values with a high level of precision 
in a clinical setting (Janda et al. 2011). 
 
A PID controller was developed to control the closed-loop administration of Propofol 
and Remifentanil, using a BIS monitor (Liu et al. 2011). The controller was 
compared with manual Target-Controlled Infusion (TCI). During induction and 
maintenance of general anesthesia, the controller allows the automated delivery of 
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Propofol and Remifentanil and maintains BIS values better than manual 
administration (Liu et al. 2011). 
2.3 Patient body Dynamics and Models 
Many models in anaesthesia are based on relations between variables such us drug 
plasma level and effect. Models can establish a relationship between variables but 
may not explain the physical basis for the relationship (Beneken & van Oostrom 
1998). 
2.3.1 Body and interaction to anaesthetic medicine 
Pharmacokinetic/pharmacodynamic modelings have made a substantial contribution 
to depth of anaesthesia by providing an insight into the factors affecting the onset 
and offset of drug effect (Schwilden & Olkkola 1991). 
 
Pharmacokinetic interactions occur when the administration of one drug alters the 
disposition of another, and hence alters the concentration of drug at the receptor site, 
leading to an altered drug response. These changes in drug concentration at the 
receptor site may be produced by an alteration of (a) drug absorption and uptake into 
the body, (b) drug distribution, (c) drug metabolism and (d) drug elimination or 
excretion by nonmetabolic routes (Kennedy & Van Riji 1998; Naguib et al. 1998). 
 
Schuttler et al. (2000) performed a multicentre population analysis to quantify the 
effects of covariates. Patients’ inter- and intra-individual variability was estimated 
for clearances and volumes. The effects of age, weight, type of administration were 
investigated. A three-compartment model for pharmacokinetics of Propofol was 
described. It also found that weight had a significant covariate for elimination 
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clearance, the two inter-compartmental clearances, the volumes of the central 
compartment, the shallow peripheral compartment, and the deep peripheral 
compartment.  
 
Minto et al. (2008) described the influence of cardiac output on the disposition of 
intravenous drugs within the first few minutes after administration of the anaesthetic. 
They also calculated intravenous loading doses that allow for the delay between the 
concentration of the anaesthetic in the plasma and the rising concentration at the site 
of drug effect. A stable level of drug effect using computerized infusion pumps that 
target the site of drug effect rather than the plasma was also achieved and 
maintained. Importantly, to consider  models of drug interaction, an understanding of 
how drug offset varies with duration of administration is required (Minto & Schnider 
2008). 
 
Copeland et al. (2008) determined whether general anesthesia affected the entire 
body and/or the local (heart and brain) pharmacokinetics of each regional anesthetic. 
Their secondary objectives were to determine whether anesthesia affected their blood 
binding, tissue concentrations, or the pharmacokinetics of the racemic regional drugs 
enantioselectively (Copeland et al. 2008). 
2.3.2 Patient body kinetics 
A model has been defined as a concept of reality, which accounts for those properties 
of a phenomenon that are pertinent to the function of the model. Models are used in 
anesthesia to identify the various physiologic, pharmacological and physical 
processes that happen during general anaesthesia. Beneken et al. (1998) introduced 
the reader to some of the types of models that had been used to facilitate education 
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and research in anaesthesia. They also elucidate the steps involved in developing a 
model and the various types of models that have proven useful (Beneken & van 
Oostrom 1998). 
 
Patient pharmacokinetics can be described by a two, three, and four-compartment 
model. Adjusting pharmacokinetics to each patient should improve the accuracy of 
target-controlled infusion and    help to extend the field of application for target-
controlled infusion (Bouillon et al. 1999). The earliest information about the 
composition of the human body was based on chemical analyses of specific organs, 
and rarely of the whole body. Development and application of the classic two-
compartment model of body composition have accelerated in recent years because of 
the association of excess body fat with increased risk for cardiovascular diseases 
(Ellis 2000). 
 
A review study was structured from the methodological point of view by Ellis in 
2000. The relations between the various in vivo methods (densitometry, dilution, 
bioelectrical impedance and conductance (Ellis 2000), whole body counting, neutron 
activation, X-ray absorptiometry, computer tomography, and magnetic resonance 
imaging) and the five-level multicompartment model of body composition were 
described, along with the limitations and advantages of each method. This review 
also provided an overview of the current status of research  in  human  biology,  
including  examples of reference  body composition  data  for  infants,  children, 
adolescents, and adults (Ellis 2000). 
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2.3.3 Patient body dynamics 
A dynamic system is a system whose states are determined by the initial conditions 
and the temporal history of the inputs after the initialization. The temporal evolution 
of its states are mathematically formalized and written as differential equations for 
continuous and difference equation for discrete systems. 
 
The purpose of a dynamic systems assumption is that the instantaneous configuration 
of a process is represented as a state in a space of states, the ”state space”. The 
temporal evolution of the process can be represented as the motion of the state in the 
state space, called orbit or trajectory. The element of the state space is defined by the 
number of state varaibles, which allows specifying uniquely the system’s behaviour 
at each point in-time. If the dimension is low enough, it can visualize the trajectory 
(De Feo 2001). 
2.3.4 Models for control 
The distribution of anaesthetic medications in the body depends on transport and 
metabolic processes (Bibian et al. 2003). Diverse models have been proposed for 
modeling the drug effect, such as experimental models, compartmental models and 
physiological models (Mahfouf, M., Asbury & Linkens 2003). The standard 
modeling paradigm that has been commonly used to describe the relationships 
between anaesthetic inputs and patient output indicators is that of compartment 
models (Bamdadian, Towhidkhah & Moradi 2008; Chilcoat 1980). 
 
Another major aspect is the stability of the controller with respect to artefacts. If 
there is sensor failure, methods of PID control cannot predict the future dose needs 
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that maintain the anaesthetic effect within reasonable margins.  The model-based 
controller can, however, be used to estimate the drug requirement during a period of 
failure when no feedback is possible. This is done on the basis  of the adapted 
pharmacokinetic-dynamic model (Schwilden & Olkkola 1991). 
 
The compartmental model is widely used in controlling of drug administration. Also,  
the  non-linear  three-compartmental patient model was used for the disposition of 
the Propofol (Eshghi, Aliyari & Teshnehlab 2009). 
2.4 Control Techniques for DoA 
The closed-loop control in medication was pioneered by Bamdadian et al. (2008) and 
Caelen et al. (2006) who established through clinical experiments that this form of 
control is secure, helpful, effective and in many cases better than manual control 
(Bamdadian, Towhidkhah & Moradi 2008; Caelen et al. 2006). 
 
Huge patient-to-patient variations in dynamic model parameters must be 
accommodated. This is compounded by the large time-varying parameters for each 
patient through the course of a surgery, which makes it even more difficult to design 
a fixed-parameter PID controller that is suitable in many cases. It indicates the need 
for more investigations into robust control strategies. In addition, model-based 
control algorithms may be more useful in this case. Intelligent systems can provide 
the best structure to develop robust predictive controllers for clinical pharmacology. 
The previous efforts to develop close-loop control of general intravenous anaesthesia 
with Propofol have used a classic adaptive controller for compartmental model and 
BIS scale to measure the depth of anaesthesia (Eshghi, Aliyari & Teshnehlab 2009). 
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2.4.1 Model based predictive control in DoA 
The concept of automated anaesthetic drug delivery has been investigated for 50 
years (Steil & Rebrin 2005). However, despite many recent studies and clinical trials, 
no real clinical breakthrough has been achieved. New advances in nervous system 
monitoring technology have yielded a new set of real-time sensors to capture the 
effect of these drugs on the patient’s state (Steil & Rebrin 2005). As a result, 
automated feedback control of anaesthetic drug delivery to a pre-defined set point 
can potentially provide the patient with a titration specifically adjusted to his or her 
needs. 
 
Propofol is a common intravenous anaesthetic drug, used for both induction and 
maintenance of general anaesthesia during surgical operations because of its 
favourable pharmacokinetic profile and its inhibition of post-operative nausea and 
vomiting. Many closed-loop feedback systems for Propofol infusion have been 
proposed in the literature. Frei et al. (1999) designed a model predictive control 
algorithm from rule based and physiological models were shown for the regulation of 
respiratory functions and cardiovascular activity. The controllers have been 
compared to manual operations on real patients, indicating higher quality anaesthesia 
for the set of patients handled by the controller (Frei et al. 1999). 
 
Rao et al. (2003) designed and developed a model-based control methodology for 
automatic regulation of mean arterial pressure and cardiac output in critical care 
using inotropic and vasoactive medications. The control algorithm has been used in a 
multiple-model adaptive approach in model predictive control structure to account 
for variability and explicitly handle anaesthetic rate constraints. The controller 
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performed better compared to experiments on manual regulation of the 
hemodynamic variables (Rao, Aufderheide & Bequette 1999 or; 2003). Gentilini et 
al. (2002) developed a model predictive control approach for the regulation of 
analgesia by infusing Alfentanil with MAP as the controlled variable. The proposed 
control was successful in the clinical setting. This method confirmed the possibility 
of achieving better hemodynamic control with the drugs that contains opium 
(Gentilini et al. 2002). Hoeven et al. (2007) described a design of a model of control 
system for a gas composition of the inhaled breath during anaesthesia. The control 
system was used to create an artificial breathing pattern, and a mechanical lung is 
used as a model of the human lung. Fresh gas was added close to the lung to create a 
rapid response, and sensors measured the properties of the gas mixture passing into 
the lung (Hoeven van der et al. 2007). Nicolas et al. (2008) developed a model to 
represent a patient subjected to general anaesthesia considering only the DoA. The 
model was built using MATLAB/SIMULINK. The algorithm was improved to be 
able to switch between two internal models. The plant (the patient model) was 
exactly one of these two models, then, the algorithm was modified to integrate a 
Model Predictive Control law instead of constant one (Cardoso & Lemos 2008; 
Furutani et al. 2010). 
 
Authors evaluated a novel model predictive controller for closed-loop administration 
of Alfentanil via mean arterial blood pressure and predicted plasma Alfentanil 
concentration (Cp Alf) as input parameters. They evaluated and  described a model 
predictive controller for the control of mean arterial pressure (MAP) as a primary and 
predicted plasma and Alfentanil concentration (Cp Alf) as a secondary input variable 
 Chapter 2   Literature Review  
 
   30 
for optimal dosing of an Alfentanil infusion rate (output variable) under the condition 
of a hypnotic state  defined according to BIS.(Luginbühl et al. 2006).  
 
Sawaguchi et al developed a hypnosis control system, which administers Propofol to 
regulate the BIS. Their study discussed three functions. First, a feedback controller 
using a MPC method which accommodated the effects of time-delays. Second, it 
dealt with a parameter estimation function of individual differences. Third, it 
discussed with a risk control function for preventing undesirable states such as drug 
over-infusion or intraoperative arousal (Sawaguchi et al. 2008). 
 
Yelneedi et al. (2009) also developed an advance control strategy for the regulation 
of hypnosis with Propofol. A reliable PK-PD model with associated parameters was 
obtained and the closed-loop response for four different types of control methods 
(model predictive control, internal model control, controller with modelling error 
compensation, and proportional-integral-derivative (PID) control) were compared. 
The performances of these controllers were considered alongside with the 
performance of the conventional PID controller. The developed, model-based 
controllers were  robust to inter-patient variability, and better at handling 
disturbances and amount noise (Yelneedi, Samavedham & Rangaiah 2009).  
2.4.2 Time-delay in DoA control  
The instrumentation and drug distribution time-delays are important factors for 
monitoring during surgery, especially in DoA for detection of awareness. Increasing 
the period of responsiveness increases the risk of recall (Dutton, Smith & Smith 
1995a). Intra-operative awareness is a rare phenomenon during general anaesthesia 
with an incidence of between 0.1 and 0.2% (Dutton, Smith & Smith 1995b, 1995a) 
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and the existing monitors cannot dependably predict awareness in advance. 
However, a monitor should at least be able to detect a consciousness reaction. Zanner 
et al. (2009) showed that all currently available monitors need varying periods to 
determine a new index when reacting to changes in anaesthetic depth. The exact 
time-delay for the calculation of new index values is unknown (Zanner et al. 2009). 
 
Several studies have been proposed in the literature investigating the effect of the 
time-delay during anaesthesia to improve intra-operative administration. Pilge et al. 
(2006) proposed a study based on the electroencephalographic analysis. Several 
parameters are used as a measure of the hypnotic component of anaesthesia. The 
time-delay of the tested indices limits the value in prevention of the recall of intra-
operative events (Pilge et al. 2006). 
 
The problem of time-delay estimation in depth of anaesthesia systems has been 
addressed with the focus on the practical applicability of methods. Four time-delay 
estimators have been  described: a cross correlation method and three increasingly 
sophisticated interpretations of the phase spectrum, ranging from a point wise 
interpretation of the phase spectrum in terms of a delay to a Hilbert transform 
method (Müller et al. 2003). Muñoz et al. (2004) measured the time to peak effect of 
Propofol in children and adults. While this time is considerably longer in children, 
the finally calculated      is particular to the model used to derive this parameter. 
 
 The     obtained from the models of Kataria and the Paedfusor for Propofol in 
children can be used with caution with the corresponding models to target effect site 
concentration of Propofol in children. They theoretically proved that the effect site is 
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a more logical target than plasma. As a result, this reduces the delay to obtain a given 
drug effect and possibly also its variability, when compared with plasma 
concentration (Muñoz et al. 2004). Heyse et al. (2009) based on the available 
literature presented a method to compare monitors of the hypnotic component of 
anaesthesia (Heyse et al. 2009). Michel et al. (2001) worked on the monitoring of 
anaesthetic depth. The aim of their study was to compare the accuracy of this new 
index with the Bispectral Index (BIS), to predicted effect-site concentration of 
propofol, and hemodynamic measures and the time-delay (Struys et al. 2001). 
Ionescu et al. (2011) introduced the cross-correlation analysis to estimate the time-
delay originating from instrumentation in intensive care unit of anaesthesia. The 
algorithm was tested on synthetic signals, ensuring its accuracy for online estimation 
purposes (Ionescu, Hodrea & De Keyser 2011). 
2.4.3 Deadbeat control in DoA 
The robust deadbeat control scheme is simpler and the performance is better (Wen & 
Lu 2008). In addition, this control scheme does not include any complicated math 
and calculation except the normalisation and look-up table. It is easily accepted by 
industrial  designers (Emami-Naeini & Franklin 1982). 
 
Malesani et al. (1999) presented a theoretical analysis of the stability robustness of 
the dead-beat control technique with respect to parameter mismatches. These are 
very likely to be encountered when considering active filter and rectifier applications 
of current-controlled voltage-source converters. The authors proposed an effective 
analysis technique, which enables one to predict the occurrence of instability 
problems, revealing the different robustness levels of the possible implementations of 
the converter’s dead-beat control. The effectiveness of the theoretical analysis and of 
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the proposed improvements have been verified by simulations and experimental tests 
on a laboratory pulse width modulator (PWM) rectifier (Malesani, Mattavelli & Buso 
1999). 
 
A new approach for deadbeat control was presented by Zhang et al. (1999), in which 
the estimation of the disturbance was carried out with a repetitive predictor instead of 
a disturbance observer. Taking advantage of repetitiveness of the loads, it gave better 
performance at lower sampling frequency. Simulations and experiments confirmed 
the advantages of this method (Zhang, Kai et al. 1999). 
 
A considered control approach is based on the combination of dead-beat control of 
inverter currents and space vector modulation. Simulations and experimental tests 
show that the intrinsic calculation delay of the dead-beat algorithm represents a 
serious hurdle for the accomplishment of an acceptable compensation quality. From 
the stability point of view, the effects of parameter mismatches on the system's 
performance are investigated by means of a complete eigenvalue analysis, which 
reveals the limits of the system's stability for different possible implementations of 
the considered control strategy  (Malesani, Mattavelli & Buso 1998). 
 
A proposed method of a simple tuning algorithm for digital deadbeat control based 
on error correlation has been investigated. The proposed solution was simple, it 
required a short tuning time, and it was appropriate for different dc–dc converter 
topologies (Saggini et al. 2007). 
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2.5 Summary 
Anaesthetists have succeeded in creating anaesthesia as a secure procedure. 
However, the present practice relies uniquely on secondary signs to warn the 
practitioner of either pharmacological toxicity or anesthetic inadequacy. On the other 
hand, much research into the closed-loop control of anaesthesia has not been adopted 
and yet not acknowledged for routine use.  
 
In the past 15 years, serious advances have been made. In 1996, practitioners had 
access to monitors to measure the degree of anaesthesia-induced unconsciousness. 
Monitors, such as the BIS, are still considered by anesthetists to be nothing more 
than gadgets. In addition, the BIS sensor price discourages the use of monitors in 
everyday practice. 
 
This literature review shows that many methods have been developed to design 
control systems with input and state constraints however; these methods do not give 
satisfactory performance in many situations. This leaves scope for the development 
of new strategies, particularly to control systems with constraints. This research will 
result in development of new control methods and algorithms, which can be used in 
various sectors to control systems more effectively. This research will also state the 
performance criterion thereby mentioning the limitations the new methods may have. 
In addition, the performance of the new methods will be validated in simulation 
experiment. 
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CHAPTER 3  
 
HUMAN BODY AND MODELS  
 
 
3.1 Kinetics and Dynamics of Human Body  
 
There are several methods for the modelling of a biological system for anaesthetic 
distribution, however the physiological mechanisms of drug circulation and drug 
effects are only partially known (Gentilini, et al. 2001). As a result, a first principle 
modeling is almost impossible. Therefore, one has to decide on approximate first 
principle physiological models (Bischoff 1975), black-box identification schemes 
(Jacobs 1988), and information based modeling. Each approache has certain 
drawbacks. In physiological models, parameters are uncertain as they collected from 
different sources where experiments may have been performed under different 
conditions (Bailey & Shafer 1991). Black-box models and knowledge based models 
suffer from poor extrapolation properties (Gentilini, et al. 2001). 
 
Experimental models are black box models (see in Figure 3.1) and relate input and 
output by an analytical term, such as a sum of exponentials (Carson & Jones 1979). 
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Compartmental models are formulated based on the minimum number of 
compartments that effectively fit observed data (Sadean & Glass 2009). 
Physiologically based models are the most realistic representation of drug kinetics, 
for the reason that the parameters relate directly to physiology, anatomy and 
biochemistry. Clearly all forms are experimental and the above definitions specify 
the approach of formulating the model rather than the resulting model. All 
formulations give a set of ordinary differential equations describing the explicit drug 
characteristics. The major two forms used in anaesthesia are compartmental and 
physiological models. The models have mismatches, which comprise individual 
differences in the pharmacokinetic-pharmacodynamic (PK-PD) parameter values and 
estimation error in the pharmacodynamic parameters. If the model is used in an open 
loop controller, these mismatches produce fluctuation of the BIS. The effects of these 
mismatches can attenuate in closed-loop systems. However, more accurate model 
improves the tracking ability and robust stability of the closed-loop control systems 
(Schnider et al. 1999). The  PK  is  identified  on  the  basis  of  input-output  data  
sequences. An input drug is administered and the time course is measured by 
taking blood samples. The infusion time of the bolus is generally neglected and 
therefore the response can be viewed as an approximation of an impulse 
response.  The blood (or more appropriately, plasma) compartments are used 
as central compartment (compartment 1). The effect-site concentration is only 
used to account for the time lag between drug concentration and drug effect 
(Schnider et al. 1999). 
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Figure 3.1: Human body modeling 
 
3.2 Pharmacokinetic Model 
Pharmacokinetics (PK) is the dynamic process of drug distribution in the body 
(Sheiner & Steimer 2000). The construction of the pharmacokinetic model is based 
on the population of pharmacokinetic model given through a large-scale multicenter 
research described by Schnider et al. (1998; 1999), Minto et al. (1997), and Schnider 
& Shafer (1997). The patient’s age and weight are included in this model and it 
seems to be sufficiently dependable, but this model does not include the effect site 
that relates directly to the BIS (Shafer & Gregg 1992). 
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The human body modeling is divided into a number of compartments to drive the PK 
model (Cardoso & Lemos 2008). In each part of these compartments, the drug 
concentration is homogeneous. The type of the anaesthetic is Propofol. 
We consider a unified model that can deal with both bolus and continuous infusion 
and has the effect-site compartment. 
The pharmacokinetic model is represented by the following equations: 
 
 
                                                           [
 ̇  t 
 ̇  t 
 ̇  t 
]    [
   t 
   t 
   t 
]      t           (3.1) 
 
where  
 
    
[
 
 
 
 
 
 
            
  
   
  
   
  
   
  
    
  
 
  
   
  
 
  
    
  ]
 
 
 
 
 
 
 
 
   [
 
  
 
 
]   
where    t       denotes the drug amount in the central compartment.  
  
  
 is the 
blood concenration. The peripheral compartments 2 and 3 represent the drug 
exchange of the blood with body tissues. The masses of drug in fast and slow (the 
concentration of Propofol) equilibrating peripheral compartments are expressed by 
   and   . In addition,   t  
  
 
  is the infusion rate of the anesthetic (Propofol) drug 
into the central compartment (the manipulated variable) (Niño et al. 2009). The 
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parameters          and    are the clearance and volume of compartment i , 
respectively, given by functions of the patient’s age and weight, height and gender 
(Marsh et al. 1991) and can be calculated for Propofol as shown in Table 3.1: 
 
Table 3.1: Pharmacokinetic parameter values (Niño et al. 2009). 
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From equation (3.2) and Table 3.1, the parameters      are calculated as follows:  
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where weight, height and age are kg, cm and years, respectively. 
 
The patient body mass (lbm) for men (m) and women (f) is considered in the 
following expressions (Ionescu, De Keyser & Struys 2011): 
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A three-compartment model can describe the PK of Propofol well. Insertion of age 
and weight as covariates considerably improved the model. Adjusting PK for each 
person should improve the accuracy of the target-controlled infusion and may help to 
extend the field of application for target-controlled infusion Propofol of DoA for 
both induction and maintenance. 
3.3 Pharmacodynamic Model 
Pharmacodynamics (PD) means the description of the effect of the drug on the body. 
A PD model presented as a low-pass filter is used to relate the plasma Propofol 
concentration   
    
 (represented by   ) in the blood and the Propofol effect site 
concentration   
    
. This yields the following state space representation:  
 
                                                                                                                       (3.5)  
 
                                                   ̇   ̇                                                 (3.6) 
 
where         ,       .and       
 
The amount of     and     are constants and    represents the drug in the effect 
compartment. The constant         in equation 3.6 is 0.456   in
    for Propofol 
(Schnider et al. 1998; Schnider et al. 1999). The effect site compartment is a very 
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small compartment has a negligible impact related to the central compartment 
(Shafer, S. et al. 1998). 
where   is: 
                                                      
   
     
                                                      (3.7) 
 
The Hill equation is an equation used in biochemical characterization. It consists of a 
static model with one (or two) input and one output (the DoA). 
The Hill equation (Bailey & Haddad 2005) is given by: 
 
                                                       
  
 
   
    
 
   
 
   
                                          (3.8) 
 
   represent the conscious state without anaesthetic, which is assigned a value of 
100;       denotes the maximum effect achieved by the anaesthetic infusion;     is 
the drug concentration at 50% of maximal effect and represents the patient’s 
sensitivity to the drug; and   represents the steepness of the static nonlinearity. A 
very important advantage of continuous drug infusion for general anaesthesia is the 
opportunity to maintain a nearly constant rate of the effect concentration of the drug 
in use (Mahfouf, et al. 2005). 
3.4 Time-Delay in Response 
Computational delays and sampling effects can critically affect the performance of a 
control system. Typically, the closed-loop responses of a system become oscillatory 
and unstable if these factors are not taken into account. Therefore, when modeling a 
control system, one should include computational delays and sampling effects to 
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accurately design and simulate a closed-loop system (Franklin, Powell & Emami-
Naeini 1994). 
 
The process of anaesthesia is nonlinear with time-delay. There are also some 
constraints in calculating  administrative drug dosage which have to be included 
(Ionescu, De Keyser & Struys 2011). Drug concentration in the patient’s body is 
estimated and this estimation is used in the patient’s model for controlling the depth 
of anaesthesia (Rezvanian et al. 2011). 
 
Propofol infusion to the BIS includes considerable time-delay. This delay is caused 
by the movement of Propofol from a three-way stopcock to the patient’s body in an 
intravenous fluid line and circulation of Propofol in blood vessels at the central 
compartment. The delay shown by the BIS monitor is between 15–60 s (Pilge et al. 
2006; Zanner et al. 2009). 
 
The BIS value BIS(t) was determined by the past value of the effect site 
concentration, as shown in equation 3.9, where   is the time-delay. 
 
                                                  t        t                                            (3.9) 
3.5 Intra-patient Uncertainty 
Intra-patient variability clearly indicates the variability observed in the drug response 
within one particular subject. This variability originates from different factors. The 
pharmacokinetics of intravenous agents differs depending on the method of the drug 
administration bolus or infusion. PK models have the same steady state gain whether 
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bolus or infusion is used. The initial peak plasma concentration following a bolus 
administration is significantly over-predicted by the corresponding infusion model 
(see Figure 3.2) (Schüttler & Ihmsen 2000; Yelneedi, Lakshminarayanan & 
Rangaiah 2009). 
P
la
sm
a
 c
o
n
ce
n
tr
a
tio
n
 [
m
g
/m
l]
Time, t (min)
10
0.12
Bolus
Infusion
 
Figure 3.2: Bolus vs infusion pharmacokinetic of propofol (Niño et al. 2009) 
 
For small setpoint changes with/without disturbances, the controller will manage 
propofol infusion at a rate approximately 0.5     in    ⁄   during steady state. 
Within this range the Propofol pharmacokinetics is expected to be accurately 
described by the infusion model. In some cases the controller must signal an increase 
in output infusion rates when the transients are above 1     in    ⁄   (Dumont, 
Martinez & Ansermino 2009). 
Importantly, the propofol amount and distribution may track and follow the behavior 
observed for bolus regulations. If the controller output is not constrained to the 
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infusion rates up to 0.5     in    ⁄  , then the controller design has to take into 
account the difference between the bolus and infusion in the dynamic of PK models. 
This difference in bolus and infusion models creates a system uncertainty. Tables 
3.4a and 3.4b show bolus infusion variation for individual cases (Bibian 2006). 
Another factor is the controller setpoint. The Hill saturation may be viewed as a gain 
that is dependent on the operating point of the system. 
 
In PK-PD  modeling, it is usual to distinguish between two different sorts of 
uncertainty, the first is the uncertainty originating from intra-patient  variability (for 
instance the variability observed within one particular individual) and the second is 
uncertainty caused by inter-patient variability such as the variability observed 
between different persons (Bibian 2006). NON linear Mixed Effect Models 
(NONMEM) is a project group, from the University of California, San Francisco, 
Canada. One of the major advantages of NONMEM  group is that inter-patient and 
intra-patient variability can be quantified. 
 
The intra-patient variability describes the residual errors resulting from assay errors, 
time-recording inaccuracy and model misspecification (Schüttler & Ihmsen 2000). 
The model for intra-patient variability assumes that the error increases with 
increasing concentrations, but this error should be centered around zero. This 
estimation indicates nonlinear for the pharmacokinetics of Propofol, which means 
that total body clearance decreases with increasing concentration (Bailey & Haddad 
2005). 
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Schüttler et al. (2000) in their  study spanning hundreds of patients  and thousands of 
blood  samples, provides the most up-to-date intra-patient variability which was 
found to be less than 20%. Their PK parameters are presented in the Table 3.2 and 
Table 3.3 (Schüttler & Ihmsen 2000). 
 
Table 3.2: Parameter estimates from the NONMEM analysis 
 (Schüttler & Ihmsen 2000). 
Parameters estimation Value            Units                   SE 
   
   
   
   
   
   
   
   
   
    
    
    
    
    
    
    
    
    
1.44                           in                       0.09 
9.3                                                           0.9 
2.25                           in                      0.31 
44.2                                                            6.1 
0.92                            in                      0.15 
266                                                              43 
0.75                                                            0.06 
0.62                                                            0.09 
0.61                                                            0.11 
0.045                                                       0.012 
0.55                                                            0.13 
0.71                                                            0.26 
-0.39                                                           0.15 
-0.40                                                           0.10 
1.61                                                             0.36 
2.02                                                             0.41 
0.73                                                             0.23 
-0.48                                                           0.12 
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Table 3.3: Propofol P K parameter sets from  (Schüttler & Ihmsen 2000). 
PK parameters   Value                                                                                           Units 
    
 
    
    
 
   
   
   
        ⁄  
   i  a e                                                                                     in    
        ⁄  
    a e          i  a e                                                     in
    
        ⁄  
       en          bo                                                     in
    
        ⁄  
       bo                                                                               in
    
 
        ⁄  
     a e   ⁄         bo                                                       
        ⁄  
      bo                                                                                
                                                                                                                             
3.6 Inter-patient Uncertainty 
Due to inter-patient pharmacodynamic variability, close-loop controllers have not 
been widely adopted clinically because control of anaesthetic concentration does not 
translate into control of anaesthetic effect (Bailey & Haddad 2005). Inter-patient 
variability (system uncertainty), non-linearity, and time-delays reveal the challenges 
inherent in biological systems (Niño et al. 2009). 
From (3.6) and (3.8) it can be seen that the drug effect is a function of the 
pharmacokinetic parameters as well as the pharmacodynamic parameters. If these 
parameters are known, it is straightforward and uncomplicated to calculate the dose 
procedure needed to achieve the target BIS signal. Because of the uncertainties in the 
pharmacokinetic and pharmacodynamic parameters due to inter-patient variability, 
these parameters are not known for each patient, and inter-patient variability may be 
significant. For some parameters the estimation for the coefficients of variability are 
as high as 100% (Haddad, Hayakawa & Bailey 2006). 
In Tables 3.4a and 3.4b, the data of American Society of Anaesthesiologists (ASA) 
shows that two patients with the same physiological characteristics (age, weight, lean 
body mass) can have largely different PK-PD parameters. For example, patient 
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number 15 in Table 3.4a (female, 21 yrs old, 53 kg, 157 cm, ASA I) and patient 
number 53 (female, 21 yrs old, 67 kg, 163 cm, ASA I) have considerably different 
PK time-delay (45 sec vs. 4 sec), EC50 parameter (3.8  g/ml vs. 2.3  g/ml), and 
saturation characteristics (Hill steepness of 1.2 vs. 2.5). 
Table 3.4a: PD models obtained (Bibian 2006) 
 
Patient 
Traditional PD approach 
 
 
Proposed PD approach 
 
LTI 
Ke0[          
Hill 
EC50 [     ]             
LTI 
Td [s]            kd [            EC50[     ] 
Hill 
  
 
 
G l:      >18  -  <30  years 
007 
008 
010 
015 
016 
023 
030 
035 
038 
046 
048 
053 
058 
066 
071 
Mean 
SD 
 
10.0  
13.8 
0.8 
1.9 
4.2 
10.7 
5.6 
8.4 
11.8 
9.9 
8.6 
9.9 
10.6 
12.9 
8.1 
8.5 
3.8 
 
1.8                                       2.9 
2.7                                       3.2 
0.4                                       3.3 
1.1                                       1.8 
1.7                                       1.9 
3.1                                       2.8 
1.8                                       3.1 
1.9                                       3.8 
3.0                                       2.6 
2.4                                       3.9 
2.2                                       3.3 
2.1                                       3.4 
1.9                                      3.0 
2.4                                       2.4 
1.8                                       2.7 
2.0                                       2.9 
0.7                                       0.6 
 
22                             133.5                                     3.2 
4                               44.4                                       3.1 
44                             25.0                                       2.4 
45                             51.5                                       3.8 
39                             85.7                                       3.8 
18                             82.5                                        3.9 
32                             44.4                                        2.9 
12                             26.7                                       1.9 
7                               35.2                                       3.4 
9                               32.8                                       2.8 
17                              46.4                                      2.8 
4                                26.2                                      2.4 
9                                50.4                                      2.5 
18                              160.5                                    3.6 
20                              75.0                                      2.5 
20.0                           61.4                                      3.0 
13.9                           40.1                                      0.6 
 
4.7 
2.5  
1.9 
1.2 
2.3 
2.1 
2.8 
2.3 
1.9 
2.8 
2.3 
2.5 
2.6 
3.9 
1.9  
2.5 
0. 8 
 
G2:  >30  -  <40  years 
006 
009 
029 
036 
047 
049 
051 
061 
063 
065 
068 
074 
Mean 
SD 
 
2.4 
5.9 
6.3 
10.9 
11.9 
8.7 
9.5 
6.1 
8.2 
17.0 
7.3 
5.1 
8.3 
3.8 
 
1.1                                       4.6 
2.2                                       2.6 
2.6                                       3.2 
2.9                                      1.5 
3.0                                       2.2 
3.0                                       2.5 
2.5                                       2.9  
1.8                                       2.9  
2.1                                       2.5 
3.3                                       2.5 
2.4                                       2.5 
2.1                                       2.1 
2.4                                       2.7 
0.6                                       0.7 
 
44                              54.8                                       3.2  
29                              83.1                                       4.0 
18                              34.4                                       3.7 
1                                29.6                                       3.3 
1                                24.9                                       3.1 
12                              35.2                                       3.9 
4                                24.8                                       2.7 
12                              28.7                                       2.8 
5                                27.0                                       2.8 
4                                 67.2                                       3.6 
12                               29.3                                       3.1 
13                               29.1                                       3.7 
12.9                            39.0                                       3.3 
12.6                            19.0                                       0.4 
 
2.7 
2.3 
2.1 
1.2 
1.5 
1.8 
2.0  
2.2 
2.1 
2.0 
1.8 
1.8 
2.0 
0. 4 
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Table 3.4b: PD models obtained (Bibian 2006) 
 
Patient 
Traditional PD approach Proposed PD approach 
LTI 
Ke0[          
Hill 
EC50 [     ]             
LTI 
Td [s]          kd [            EC50[     ] 
Hill 
  
G3:  >40  -  <50  years 
004 
025 
027 
040 
042 
043 
052 
069 
072 
Mean 
SD 
 
2.1 
9.5 
15.3  
10.8 
7.2 
7.7 
11.7 
9.8 
5.4 
8. 8 
3. 8 
 
0.9                                       2.6  
4.4                                       1.9 
4.7                                       2.2 
4.1                                       2.4  
2.8                                       2.5 
2.8                                       2.5 
3.2                                       3.1 
2.7                                       2.9 
1.7                                       2.5 
3.0                                       2.5 
1.2                                       0.4 
 
35                               38.0                                       3.3 
11                               36.6                                       6.1 
2                                 32.6                                       4.7 
12                               35.0                                       4.5  
10                               28.7                                       3.9 
12                               34.8                                        3.9 
9                                 36.6                                        3.2 
8                                 35.6                                        3.4 
13                               30.0                                        3.0 
12.4                            34.2                                         4.0 
9.1                              3.1                                           1.0 
 
1.8 
1.3 
1.3  
1.4 
2.0 
1.8 
1.9 
2.3 
1.9 
1.7 
0. 3 
 
G4:  >50  -  <60  year018 
018 
033 
041 
057 
060 
 064 
070 
075 
Mean 
SD 
 
11.9  
4.4 
8.3 
5.4 
7.0 
12.7 
8.7 
5.2 
8.0 
3.1 
 
3.1                                       3.1 
2.3                                       1.8 
3.7                                       1.6 
2.2                                       1.6 
2.7                                       2.6 
3.9                                       1.3 
3.1                                       2.1 
1.8                                       2.4 
2.9                                       2.1 
0.7                                      0.6 
 
3                                 31.5                                         3.5 
29                               42.0                                         4.4  
2                                 21.8                                         4.7 
16                               28.8                                         3.7 
10                               26.4                                         4.0  
6                                 58.0                                         5.0 
6                                 32.2                                         4.2 
12                               24.3                                         3.1 
10.5                            33.1                                         4.1 
8.8                             11.8                                        0.7 
 
2.3  
2.2 
1.4 
1.1 
1.9 
1.5 
1.5 
1.8 
1.7 
0.4 
 
Table 3.5: Propofol PK-PD inter-patient variability (Bibian 2006) 
  
Td  
 
kd  
 
EC50  
 
  
 MIN   MAX   Td,0      
[s]     [s]      [s]      [%] 
MIN   MAX   Kd,0     
[       [       [       [%] 
MIN      MAX    Kd,0        
[     ] [     ] [     ]   [%] 
MIN  MAX            
[l]       [l]      [l]    [%] 
Age group 
G1 
G2 
G3 
G4 
 
4        45      24.5   83.7 
1       44      22.5    95.6 
2       35      18.5   89.1 
2       29      15.5   87.1 
 
25.0     160.5 92.7 73.0 
24.8     83.1   53.9  54.0 
28.7     38.0   33.3  13.9 
21.8     58.0   39.9  45.4 
 
1.9          3.8       2.8           33.3 
2.8          4.0       3.4           17.6 
3.0          6.0       4.5           33.3 
3.1          5.1       4.1           24.4 
 
1.9      4.7    3.3   42.4  
1.2      2.7    1.9   38.5  
1.3      2.3    1.8   27.8  
1.1      2.3    1.7   35.3  
Population 1         45      23     95.6 21.8    160.5  91.1   76.1 1.9        6.0         4.0        51.9 1.1     4.7     2.9    62.0 
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Table 3.6: Intra- and inter-patient variability (Bibian 2006) 
 
 
 
Td  
 
kd  
 
EC50  
 
  
 MIN   MAX   Td,0      
[s]     [s]      [s]      [%] 
MIN   MAX   Kd,0     
[       [       [       [%] 
MIN      MAX    Kd,0        
[     ] [     ] [     ]   [%] 
MIN  MAX            
[l]       [l]      [l]    [%] 
patient  
1 
2 
3 
4 
5 
 
23      29     26.0    11.6 
15      23     20.5    12.2 
8       17      13.5    25.9 
25     45      35.0    28.6 
25     42      33.5    25.4 
 
17.4    67.9    42.7    59.2 
30.5    46.2    38.4    20.5 
48.5    81.5    65.0    25.4 
26.0    39.8    32.9    20.1 
37.1    214.0  125.5  70.5 
 
17.2       22.1       19.7        12.5 
14.5       15.9       15.2        4.6 
15.3       21.5       18.4        13.8 
16.4       21.4       18.9        13.2 
20.2       28.2       10.2        16.5 
 
1.4    1.6      1.5    6.7 
1.5    1.8      1.7    9.1 
1.3    1.6      1.5    10.3 
1.6    2.1      1.8    33.5 
1.2    1.5      1.4    7.1  
 
Population 
 
8        45     26.5    69.8 
 
17.1    214.0  115.5  85.2 
 
14.5       28.2       21.4        32.1 
 
1.2    2.1      1.6    27.3 
 
 
Considering the differences between PK-PD models obtained over a large population 
of patients, the inter-patient variability can be easily characterized. Table 3.4a and 
3.4b provide a good representation of an adult population with respect to the 
response to propofol administration (Bibian 2006). The parametric variability 
observed between the different PK-PD models presented in tables 3.4a and 3.4b are 
shortened in Table 3.5. 
 
As we can see, there is a considerable difference in the PK time-delay and PD time-
constant between patients. At the same time as the EC50, variability is more limited, 
there is still a six-time difference in terms of the overall PK-PD steady-state gain. To 
quantify intra- versus inter-patient parametric variability, a clinical study was carried 
out in 2002 involving five patients receiving electro-convulsive shock therapy ( ECT 
) (Bibian 2006). These patients were given a total of six treatments over two months. 
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Each treatment consisted of the administration of a single Thiopental induction dose 
to provoke a fast loss of consciousness before the application of the electric shock. 
The PK part of the model was derived based on a published Thiopental PK parameter 
set. The model parameters derived during these multiple repeats are presented in 
parametric uncertainty in Table 3.6. 
3.7 Summary 
In this chapter, the Pharmacokinatic and Pharmadynamic uncertainty are 
investigated.   This uncertainty stems from both inter- and intra-patient variability in 
drug disposition and effect. The limition of the  PK-PD  models  to  a  certain  age  
bracket  and  constraining  the  control  action  to   infusion reduce  the  uncertainty  
while  not  adding  complexity to  the  controller  design. 
 
Recent  advances  in  non-linear  regression  analysis  have  already allowed 
pharmacologists  to  characterize  Pharmacokinatic parameters  which  account  for  
the  effect  of the  age,  weight, gender. The large  variability  observed  between  
patients  and  the  discrepancies  between  the  model parameters published in   the  
literature  explain the  lack of enthusiasm  in the  anaesthesia  community  for  
Pharmacodynamic  models.  However, the  poor  performance  of these models stems 
mostly from  a  poor  choice of the  model  structure rather  than  an  inherent  
limitation  of  the  system.   
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CHAPTER 4  
 
DOA INTERNAL MODEL 
CONTROL USING SIMPLIFIED 
PATIENT MODEL 
 
 
4.1 Internal Model Control Technique 
During surgery the anaesthetist carefully controls the delivery of anaesthesia given to 
the patient in an effort to attain and maintain a consistent and adequate level of DoA 
(Bamdadian, Towhidkhah & Moradi 2008). In this process, the anaesthetist  is  
acting  as  a  manual  feedback controller  (Dumont, Martinez & Ansermino 2009). 
As there are no direct means of assessing a patient’s level of consciousness during 
surgery, the performance  of  the process  relies  on  the  experience  of  the 
anaesthetist (Weber et al. 2004). The  decision  for  the  initial anaesthetic level is 
generally made by using the recommended drug  dosages based on different  patient  
characteristics,  such  as  age  and  weight (Alonso, Lemos & Mendonca 2008; 
Schüttler & Ihmsen 2000). The  anaesthetist  determines  any subsequent alteration in 
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the anaesthetic level by observing physical signs from the patient (McAnulty, 
Robertshaw & Hall 2000).  These  physical  signs,  the  indirect  indicators of the 
DoA, may include changes in blood pressures or heart rate, lacrimation (the 
production of tears in the eyes), facial grimacing, muscular movements, spontaneous 
breathing, diaphoresis (sweating, especially sweating induced for medical reasons), 
and other signs that may predicate awareness (Bequette 2007). However, these are 
not reliable indicators of changes in patient level of consciousness. Although an 
anaesthetist can adjust recommended anaesthetic   dosages based on individual 
patient characteristics, these adjustments cannot always account for variability in 
patient responses to anaesthesia or changes  in  anaesthetic requirements  during  the  
course  of surgery (Bruhn 1999; Bruhn et al. 2006). Closed-loop administration of 
anaesthetics during surgery promises to supply a number of benefits such as 
minimising the over all amounts of drugs required to  reduce recovery time, which 
also reduces cost and allowing the anaesthetist to focus on more critical  safety tasks  
(Foster, Bojak & Liley 2008). 
 
However, the feedback controls require schemes, a mathematical model of the 
patient, and drug delivery for the design and implementation. The proposed robust 
internal model control (RIMC) uses the approximate linear   pharmacokinetic-
pharmacodynamic (PK-PD) model in the controller design, and regulates the 
patient’s Bispectral Index (BIS) by manipulating the infusion rate of propofol.  
Extensive simulations are conducted to investigate the robustness of the proposed 
RIMC controller, by considering parameter variations in the selected model to 
account for patient model mismatch.  The proposed RIMC scheme has also been 
evaluated for disturbance rejections. The main contributions of this study are to 
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demonstrate the control of hypnosis using RIMC, and to compare its performance 
with the traditional PID controller. 
4.2 Patient Model for IMC Control 
As shown in Figure 4.1, the human body is generally divided into different parts of 
compartments to drive the pharmacokinetic (PK) model (Cardoso and Lemos, 2008). 
The DoA model considers both Propofol and Remifentanil since the latter has a non-
negligible effect on the DoA level. 
 
Hereafter,   
     (the Remifentanil effect concentration) is assumed to be given and 
only the Propofol chain is considered. The Propofol infusion rate “     ” is called 
“ ” 
where   is the manipulated variable. This yields the continuous linear state space 
model given in equation 4.1. 
 
Cp
Ce
Ce
CpPropofol
Hypnotic
Remifentanil
Analgesic
DoA level
Pain levelPharmaco-
kinetic model
(PK model)
Effect 
compartment
Pharmacodynamic model 
(PD model)
Interaction 
model
Effect 
compartment
Pharmaco-
kinetic model
(PK model)
 
Figure 4.1: Depth of anaesthesia model for internal model control 
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The PK model provides the Propofol plasma concentration from a given dose of 
Propofol injected into the patient, as it can be seen in Figure 4.2. A three-
compartment model is used, in which the main compartment represents intravascular 
blood (blood within arteries and veins) and highly irrigated organs (such as heart, 
brain, liver and kidney). The other two compartments represent muscles, fat, and 
other organs or tissues (Volyanskyy, Haddad & Bailey 2009). 
 
(Propofol) 
Infusion rate 
K 10
K 13K 21
Compartment 2 Compartment 3Compartment 1
K 12 K 31
 
Figure 4.2: Pharmacokinetic compartments model 
 
                                  {
  ̇            
  
    
                  
                                                            (4.1) 
 
with     [
            
   
   
 
   
   
 
   
 
    
] 
   [
   
    
 
 
]  ,     [
 
       
  ] and 
 Chapter 4   DoA Internal Model Control for Simplified Patient Model  
 
   55 
    ei ht      
 
where    is measured with the weight of the patient and coefficient    [L/kg] which 
represents the volume of compartment one per patient unit weight [kg] (Gentilini, et 
al. 2001). 
 
A pharmacodynamic model presented as a low-pass filter is used to relate the 
Propofol plasma concentration   
    
 and the Propofol effect concentration    
    
. 
This yields the following state space representation (Niño et al. 2009): 
 
                                       {
  ̇             
    
  
    
                  
                                                        (4.2) 
 
where     =    ,         and       . 
 
The effect-site concentration is related to DoA as Hill equation (Munson & Bowers 
1967): 
 
                                        t         
  
 
    
 
   
                                                    (4.3) 
 
where     is: 
 
                                           
   
     
                                                                (4.4) 
 
where      is the inverse of the effect-site compartment time constant and      is the 
half-maximal effective concentration. 
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The mathematical model employed in this study on hypnosis and analgesia control is 
a combination of a linear PK model and a nonlinear PD model. The PK model 
parameters can be approximately estimated through covariate adjustments of weight, 
age and sex, but it is not possible to estimate the PD parameters.  The designed 
controller should be robust and result in stable responses for all patients 
characterized by a range of PD parameters. From a clinical point of view, a perfect 
controller would lead the induction of anaesthesia in order to achieve the goal as fast 
as possible without initial overshoot. After that, the controller would simply keep up 
the desired target as well as possible. 
4.3 Controller Design and Implementation 
The internal model control principle states that a plant or a process can be controlled 
only if the control system incorporates or encapsulates, either implicitly or explicitly, 
some representation of the process (Lee, Morari & Garcia 1994). For example in an 
open loop control, the model of the process to be controlled is almost exactly known 
(Kaya 2004). However, an exact model of the plant is not known in almost all 
practical cases and process-model mismatch is very common. These uncertainties 
and un-modelled dynamics in the system usually affect system performance. In such 
cases Internal Model Control (IMC) is found to be very useful (Tan, Marquez & 
Chen 2003; Yelneedi, Samavedham & Rangaiah 2009). 
 
The disadvantage of the linear IMC controller is that it cannot handle open-loop 
unstable systems and nonlinear models should be linearized for the controller design 
as shown in Figure 4.3. where       is the controller and it is used to control the 
 Chapter 4   DoA Internal Model Control for Simplified Patient Model  
 
   57 
process,      . Assuming   ̃    is a model of      . The inverse of the model of the 
process is equal to       , 
 
                                                  ̃   
                                                             (4.5) 
 
And if         ̃   , this means the model is an exact representation of the 
process. Then it is obvious that the setpoint and the output will always be equal. 
 
Set-point R(s)
Gc(s)
Process
Gp(s)
Process 
Model of
Gp(s)
Disturbance
D(s)
         
          +
  _
   
   +
    _
   +
   _
Output Y(s)  E(s) U(s)
 
Figure 4.3: Block diagram of the Internal Model Control 
 
 
This means that we must have complete knowledge about the process under control 
with perfect control performance. This also means that the feedback control is 
necessary only when information about the process is incomplete and imprecise. As 
process-model mismatch is common, that means the invertible of the process may be 
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complicated and as a result the system is often affected by noises and unknown 
disturbances. The disturbance affecting the system is D(s) in Figure 4.3. The 
planning input U(s) is introduced together with the model and the process (Yelneedi, 
Samavedham & Rangaiah 2009). The difference between the process output Y(s), 
and the output of the model is the signal ̃   . The  ̃    can be found as: 
 
                                  ̃    {        ̃   }                                            (4.6) 
 
From equation 4.6, if D(s) is equal to zero, then  ̃    is the measure of the difference 
in behaviour between the process and its model. Also if         ̃   , that means 
  ̃    is equal to the unknown disturbance or noise. As a result  ̃    is regarded as 
the information that is missing in the model,   ̃   , and can be used to improve 
control. The control signal can be written as, 
 
     [      ̃   ]        
                                    {     [           ̃   ]         }                         (4.7) 
 
Because                     then the closed loop transfer function for IMC is 
equal to: 
 
                               
                      
  [        ̃   ]     
                                                   . ) 
     
From the equation 4.8, we can see that, if          ̃   
   and if         ̃   , 
that means perfect setpoint tracking and disturbance rejection is accomplished. Also 
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we can see that, theoretically, if          ̃   , perfect setpoint tracking and 
disturbance rejection can still be realised provided         ̃   
  . Furthermore, to 
advance robustness, the process model mismatch and its effects should be minimised. 
Because a distinct difference and failure to match between process and model 
performance usually occur at  the high frequency end of the system’s frequency 
response, a low pass filter        is usually added to attenuate the effects of process 
and model discrepancies (Linkens & Mahfouf 2000). As a result, the internal model 
controller is usually designed as the inverse of the process model in the series with a 
low-pass filter. 
The structure of the RIMC in DoA is depicted in Figure 4.4. The blocks PK and PD, 
together with the nonlinear equation, represent the patient’s pharmacokinetics and 
pharmacodynamics, respectively.  Both PK and PD are single-input single-output 
linear time invariant (LTI) systems. The equivalent parallel models for the 
pharmacokinetics and pharmacodynamics are represented by     ̃  and   ̃ 
respectively together with linearization constant K. 
 
where    
     
     
   
 
In Figure 4.4, the controller    regulates the BIS by adjusting the input (infusion 
rate) of the Propofol based on the difference between set point and the actual BIS. A 
saturated block is added after the controller     to keep the input within the 
constraints specified. Because the controller    is the filtered inverse of the nominal 
patient model, the tuning of the RIMC depends on the filter time constant,   and 
order of the filter, n. By adjusting this filter time constant, we can handle inter-
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patient variability for each patient for robustness and for speed response (Brosilow & 
Joseph 2002). 
Gc(s)
+
+
_
KP
~
DP
~
u Cp
Estimated 
C1
Ce
PD
K
e yr
PK
_
 
Figure 4.4: Block diagram of the IMC structure 
4.4 Simulation and Results 
The data from hospitals is recorded into a Matlab spreadsheet. In the case of 
hardcopy form, the data is manually entered into the Matlab spreadsheet. These data 
are collected and analysed to establish the relative importance of each independent 
variable in the prediction. The data analysis results are integrated for model 
development. The models are developed and designed based on this data analysis, 
and initial results are presented. Then simulations are carried out to study the 
feasibility and reliability. Testing is scheduled to the final stage of model 
development. In this study, however, the IMC is used to generate and provide a much 
easier framework for the design of robust control systems. 
The proposed control schemes were implemented and tested in simulation using 
Simulink. The nonlinear DoA model is shown in the block diagram in Figure 4.5. To 
perform these actions, a Matlab program was developed to compute parameters for 
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both linear and nonlinear Simulink models. The Matlab programs were developed to 
evaluate the influence of several parameters (     , and     
    
  ) on the nonlinear 
model. The simulations evaluate the influence of drugs in steady state on the Hill 
equation. The BIS and the infusion rate in typical cases are shown. 
Figure 4.6 shows the closed loop implementation in Simulink for controlled output 
(BIS) using RIMC. The controller performance over the family of the patients is 
affected due to inter-patient variability, when using a nominal model for RIMC 
strategy. Notice that the IMC strategy includes an identification of the patient 
specific parameters, and therefore, takes into account the patient variability to obtain 
a better control performance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5: The block diagram of DoA model built in Simulink 
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The proposed algorithm is simulated using the patient’s parameters (in Table 4.1) for 
all 15 patients model (the infusion and the drug effect are represented by the PK and 
PD models), and the amount of the drug is varied between 3 and 7       for the 
target (BIS =40). The observed time to target in seconds is required for reaching first 
time the target interval of  (between 45, 55) BIS values. Because of plasma Propofol 
concentration measurement is unavailable, it is estimated through the nominal PK 
model. BIS is measured online. The controller has maintained BIS between 40 and 
60 during the period of surgery. First, it is assumed that the patient is in a fully awake 
state  BIS≈100) and then the controller is turned on, and the set point is changed 
manually from 100 to 50. Set point changes are often made in the variables during 
the operation depending on the surgical procedure being performed. The controller 
should perfectly respond to these changes without any considerable delay in the 
response. This condition brings the patient to the surgical operating range       0 ≤ 
BIS ≤60) which must be maintained for the period of the surgery. 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Non-linear DoA model built in Simulink 
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Table 4.1: Values of the parameters for the 15 patients Sets arranged in the 
decreasing order of their BIS sensitivity to Propofol infusion 
 
 
 
 
 
 
Parameter 
 
 
Patient no.            k10          k12           k21               k13              k31             ke0        EC50     γ 
 
1 (sensitive)    0.08925     0.084       0.06875    0.031425    0.004125        0.459      1.6      2  
2                       0.14875    0.14         0.04125    0.052375    0.004125        0.239     1.6      2 
3                       0.14875    0.112       0.04125    0.0419         0.004125       0.239     1.6     3.133 
4                       0.14875     0.14         0.04125    0.052375   0.004125        0.239     1.6     3.133 
5                      0.08925     0.084      0.04125     0.052375    0.002475        0.459     2.65    2.551 
6                      08925        0.084       0.06875    0.031425    0.002475        0.349     2.65    2.551 
7                      0.14875     0.112       0.06875    0.031425    0.002475        0.459     2.65    2.551 
8 (nominal)    0.119         0.112       0.055         0.0419        0.0033            0.349     2.65    2.551 
9                       0.119         0.112      0.055         0.0419       0.0033             0.239     2.65     2 
10                     0.119         0.112       0.055        0.0419       0.0033             0.239   2.65     2.551 
11                     0.08925    0.084       0.06875    0.031425    0.002475         0.459     3.7       2 
12                     0.14875    0.112       0.06875    0.031425    0.002475         0.349     3.7       2.551 
13                     0.08925   0.084       0.06875     0.031425    0.002475         0.239     3.7       2.551 
14                     0.08925    0.084       0.06875    0.031425    0.002475         0.239     3.7       3.133 
15                     0.08925    0.084       0.04125    0.052375    0.002475         0.239     3.7       3.133 
(insensitive) 
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The predicted plasma Propofol concentration must be among 1 μg/mL and 5 μg/mL. 
The lower bound guarantees a lowest amount delivery of anaesthetic, whereas the 
upper bound prevents overdosing of the drug for an average subject. The 
manipulated variable (Propofol infusion rate)   is constrained between 0 and 40 
mg/kg/h. The higher bound is needed because higher Propofol infusion leads to a 
rapid increase of Propofol concentration in the subject’s body and this may lead to 
hypnotic crisis, cardiac arrhythmia, or even cardiac arrest. The lowest amount bound 
on   reflects the impossibility of administering negative concentrations of Propofol. 
Because the safe regulation of the DoA level is crucial during the surgery, the 
constraints imposed on the inputs are hard constraints. That is, at any time the 
controller should not violate these limits. The modification parameters for the RIMC 
controller are the filter time constant   , which is set at 1.7 and the order of the filter 
n which is set at 2. Here also, the value of   used is -24.16. For the PID controller, 
the tuning of the three parameters (   ,    and    ) is required to get faster response 
of BIS without any offset or oscillations. Here, the PID parameters are obtained 
using the optimization toolbox of Matlab to get the best performance with this 
control structure. With the PID controller, the settings were                
     , and           
 
During the induction phase, (the control execution interval is set between 5 and 10 
seconds, which is the sampling interval for BIS), the IMC strategy is relatively high 
performing. The IMC controller brings the BIS variable to the reference interval; the 
input variable (drug infusion rate) is restricted between 0 to 40 mg/kg /h. The results 
in this study can be attributed to the fact that the RIMC controller is a more cautious 
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controller, giving an exchange among small time-to-target, small undershoot and 
robustness against patient variability as shown in Figure 4.7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7: Performance of the IMC controller 
 
The response of a PID controlled system is faster than that of the IMC controller, and 
a small offset persists throughout the simulation time. Figure 4.8 shows the predicted 
plasma Propofol concentration, where it is seen that both controllers result in 
overshoot (higher with PID controller) but are still maintained within the constraints.  
The results of this study indicate that the two controllers are able to meet 
performance specifications despite significant and reasonable variation in the model 
parameters (inter- patient and intra-patient variability) as shown in Table 4.1. At this 
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point, we assume that variability in both the PK and PD is depending on the patient’s 
model parameters and on the patient’s sensitivity to the drug.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8: Performance of the PID controller 
 
The current study found that the variability in PD parameters has a higher impact on 
BIS than the variability in PK parameters. First, each                         
   and     PK parameter is assumed to be different over three levels, from a 
minimum, to average, and then to a maximum. Simulations showed that changes in 
volumes of the three compartments (      and   ) has a very small amount effect 
on the performance. For the insensitive patient, running down rate constants of the 
central compartment          and      are high (0.148, 0.139, and 0.05211, 
respectively) and generating rate constants           are low (0.042, and 0.00219, 
respectively) as shown in Figure 4.9 and Figure 4.10. 
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Figure 4.9: Performance of the IMC for two insensitive patients 
 
 
 
Figure 4.10: Performance of the IMC for different patient 
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In the PD parameters, higher      (3.6) indicates the need for more drug to obtain 
the same DoA level, higher   (3.1119) represents higher nonlinearity and lower     
(0.2388) indicates sluggishness in response as can be seen from the Figure 4.11 and 
Figure 4.12. 
 
 
Figure 4.11: Performance of the PID for different patients 
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Figure 4.12: Performance of the PID for two insensitive patients 
 
 
For the sensitive patient,         and     are low (0.09, 0.0839, and 0.0321, 
respectively) and          are high (0.0691, and 0.0039, respectively). In the PD 
parameters, lower      (1.6) indicates the need for a smaller amount of drug to 
obtain the same DoA level, lower   (2) represents lower nonlinearity, and higher     
(0.459) indicates more rapid responses. Furthermore, since     represents the process 
gain, higher     (higher gain) represents a faster response and lower     (lower gain) 
represents a slower response of the process. This can be seen from the Figure 4.13, 
Figure 4.14 and Figure 4.15(Niño et al. 2009). 
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Figure 4.13: Parameters influence on the DoA and on     
Figure 4.14: Performance of the IMC and PID controller 
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Figure 4.15: Performance of the IMC and PID controller 
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4.5 Conclusions  
In this study, a robust internal model control, for regulation of anaesthesia using BIS 
as the controlled variable, has been developed and evaluated thoroughly. The 
performance of this controller is considered along with the performance of the 
traditional PID controller. In comparison with traditional PID controller, the 
proposed robust internal model control is found to be robust to intra- and inter-
patient variability, and better at handling disturbances and measurement noise. In 
system performance, the settling time has been shortened (  5 min) and the 
performance had no undershoot in the RIMC. Undershoot was higher with PID 
controller.  The performance of the IMC controller is found to be better and hence, it 
is recommended for DoA control. The proposed RIMC strategy was also found to be 
more robust to intra- and inter-patient variability. 
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CHAPTER 5  
 
SMITH PREDICTIVE CONTROL 
FOR PATIENT MODEL WITH 
TIME-DELAY  
 
 
5.1  Human Body Model for Depth of Anaesthesia Control 
Advanced control methodologies have been and are being extensively developed for 
highly complex engineering systems.  Specifically, robust control systems have been 
developed that ensure system stability and performance in the expression of system 
modeling uncertainty, system disturbances, and system nonlinearities. However, 
modern control technology has received far less consideration in medical control 
systems such as depth of anaesthesia control. One of the main reasons is the steep 
barriers to communication between mathematics/control engineering and medicine. 
However, this is slowly changing and there is no doubt that control-system 
technology has a great deal to offer medicine. This is particularly true when dealing 
with critically ill patients in the intensive care unit or in the operating room. These 
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patients often  require the administration  of  drugs  to  regulate  key  physiological  
variables,  such  as  level  of consciousness, heart rate, blood pressure, ventilator 
drive, etc., within desired targets (Sreenivas et al. 2009). The rate of administration 
of these drugs is critical, requiring constant monitoring and frequent adjustments. 
Open-loop control (manual control) by clinical personnel can be tedious, imprecise, 
time-consuming, and sometimes of poor quality. Hence, the need for closed-loop 
control in medical systems is significant, with the potential for improving the quality 
of medical care as well as curtailing the increasing cost of health care. 
 
During anaesthesia, there is a time-delay between the administration of the drug and 
the start of mixing in the central nerve system, estimation of the time-delay is an 
important issue in surgery (Gentilini et al. 2001; Zanner et al. 2009). The 
pharmacokinetic time-delay is consistent for each individual patient, but can vary 
significantly between different patients. Researchers found that intra-patient 
parametric  uncertainty  reaches  30 % at  most  for  the  PK time  delay,  while  
inter-patient  uncertainty  can  be as  high  as  70 % (Bibian 2006). Similar results 
were found for the overall pharmacokinetic-pharmacodynamic gain (Dumont, 
Martinez & Ansermino 2009; Yue & Han 2005). The origin of the time-delay is the 
period from the start of infusion pump until the drug is distributed along the central 
nerve system; the TD varies from one time instant to another, dependent on the 
signal quality. If not dealt with appropriately, such varying TD are a source of poor 
feedback control in the medicine system (Kaya 2004; Robayo et al. 2010). 
 
For  this  study,  the  open  loop   transfer  function  is followed  by  a time  delay 
modeled using a 1
st
 order Pade approximation. The structure of the Pade 
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approximation enables an effective reconstruction of a function's singularities over 
the whole range using its series expansion obtained for small values of its variable 
(Lucchese & McKoy 1983). 
 
The aim of this chapter is to establish and validate a TD estimation method using 
Smith Predictive Control (SPC) to overcome the lack of TD information for closed-
loop sedation in surgery. This study addresses two types of time-delays, 
instrumentation and non-instrumentation time-delay during anaesthesia induction and 
the effect of that time-delay on DoA system responses. This study investigated the 
situations with and without time-delays. The results show that the proposed scheme 
has reduced   system response overshoot and undershoot by about 15%, and reduced 
the settling times by about one to two minutes. 
 
The  patient’s  body  is  divided  into  several  compartments  to  drive  the  
pharmacokinetic model (Sreenivas, Lakshminarayanan & Rangaiah 2007). In each 
compartment, the drug concentration is homogeneous as shown in Figure 4.2. The 
most common hypnotic drug is propofol that used in general anaesthesia. The 
distribution of this drug in the body can be described by   pharmacokinetic   and   
pharmacodynamic models (Van Poucke, Bravo & Shafer 2004; Volyanskyy, Haddad 
& Bailey 2009). The BIS ranges between 0 and 100 and it is related to the effect of 
the hypnotic drug by a nonlinear relation called the Hill curve (Nunes et al. 2005; 
Sreenivas, Lakshminarayanan & Rangaiah 2007).  Zero means that the patient does 
not have cerebral activity and a 100 denotes full consciousness. The PK model 
provides the Propofol plasma concentration from a given dose of Propofol injected to 
the patient. 
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PK model is expressed as: 
 
                     
     
    
 
 
      
 
 
      
 
 
      
                                     
 
where        is  the  drug  concentration  expressed  in  microgram  per  milliliter  
(Propofol),    and     in the above formula would refer to the rate  constant  of the  
distribution phase, and    is  the  rate  constant  of the  elimination phase. 
     is the control input. 
 
PD is expressed as: 
 
                                                
   
       
 
 
     
                                                         
 
where     is the inverse of the effect-site compartment time constant and      is the 
half-maximal effective concentration. 
 
The Hill curve is represented by the following equation: 
 
                                                t           
  
    
  
        
                                 (5.3)  
 
   denotes  the  baseline  value  (awake  state)  and  by  convention  a  value  of  100  
is  assigned.       denotes the maximum effect achieved by the drug. Ce is the drug 
effect-site concentration,      is the drug concentration at half-maximum effect and 
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represents the patient’s sensitivity to the drug, and   determines the steepness of the 
curve. 
 
The patient’s PK and PD models are used to predict the BIS output as a result of drug 
infusion. The generalized PK-PD model for Propofol is shown in Figure 5.1. 
 
CeCp
DoA level
Pharmacodynamic model 
(PD model)
Interaction 
model
And
DoA 
Time-delay
Effect 
compartment
Pharmaco-
kinetic model
(PK model)
Propofol
Hypnotic
 
Figure 5.1: Depth of anaesthesia model for Smith predictive control 
 
The total time-delay can be categorized into two parts. The first is related to the 
instrumentation parts, representing the time-delays at the instrument devices and the 
second are related to the dynamic response of the patient (non-instrumentation delay) 
as shown in Figure 5.2. 
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Figure 5.2: Feedback control system for SPC 
 
5.1.1 Time-Delay estimation 
During surgery, when the patient arrives at the intensive care unit, the desired BIS 
target should be 50 and must remain between 40 and 60 for a good sedation level. At 
around 50 BIS can be approximated linearly by a line, using this relationship: 
 
                                                    t  a    t  b                                             (5.4) 
 
where a represents  the  slope  of  the  linear  approximation and b is  a  constant.   
 
The real values of the parameters for the selected 12 patient sets  given in Table 5.1 
have been taken from Yelneedi, Samavedham & Rangaiah (2009) and the simulated 
BIS signals were obtained based on the scheme presented in Figure 5.3. The Propofol 
infusion is applied to the patient and the real BIS signal is recorded by the BIS  
 Chapter 5   Smith Predictive Control for Patient Model with Time-Delay  
 
   79 
Table 5.1: Values of the parameters for the 12 patients sets arranged in the 
decreasing order of their BIS sensitivity to Propofol infusion 
Parameter 
 
Patient no. 
 
k10 
 
k12 
 
k21 
 
k13 
 
k31 
 
ke0 
 
EC50 
 
γ 
 
 (sensitive)        1 0.08925 0.084 0.06875 0.031425 0.004125 0.459 1.6 2 
2 0.14875 0.14 0.04125 0.052375 0.004125 0.239 1.6 2 
3 0.14875 0.112 0.04125 0.0419 0.004125 0.239 1.6 3.133 
4 0.14875 0.14 0.04125 0.052375 0.004125 0.239 1.6 3.133 
5 0.08925 0.084 0.04125 0.052375 0.002475 0.459 2.65 2.551 
6 0.14875 0.112 0.06875 0.031425 0.002475 0.459 2.65 2.551 
(nominal)       7 0.119 0.112 0.055 0.0419 0.0033 0.349 2.65 2.551 
8 0.119 0.112 0.055 0.0419 0.0033 0.239 2.65 2 
9 0.119 0.112 0.055 0.0419 0.0033 0.349 2.65 2.551 
10 0.08925 0.084 0.06875 0.031425 0.002475 0.459 3.7 2 
11 0.14875 0.112 0.06875 0.031425 0.002475 0.349 3.7 2.551 
(insensitive)   12 0.08925 0.084 0.04125 0.052375 0.002475 0.239 3.7 3.133 
 
 
monitor. The same Propofol infusion rate is used in the simulator to obtain the 
simulated BIS signal. Using the PK-PD patient model, the effective concentration of 
the drug is calculated. The simulated BIS signal is related to the effective 
concentration of the drug by the Hill curve. A delay is added to simulate the time-
delay introduced by the real monitor. 
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Figure 5.3: The representation of the real and simulated BIS 
 
With the time-delay introduced by the BIS monitor, the real BIS signal can be 
expressed by the following relationship (Robayo et al. 2010): 
 
                                            t  a    t     b                                              (5.5) 
 
If there are no disturbances, the simulated BIS signal can be expressed by: 
 
                                          ̂  t  â    t   ̂  b̂                                              (5.6) 
 
where: a and â are the slopes of the linear curve for real and  simulated  cases,  
correspondingly, b  and b̂ represents  the intersection of the line  with the BIS axis  
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for the real and simulated cases, correspondingly,   and  ̂are the time-delays in   
samples   for   the   real   and   the   simulated   cases, respectively. 
 
If     ̂  is the difference between the time-delay of the real BIS signal and the 
time-delay of the simulated BIS signal, the linear relation between real BIS and 
simulated BIS is obtained by (Robayo et al. 2010): 
 
                                            t  ã   ̂  t   ̃  b̃                                              (5.7) 
 
where ã  a â⁄ , b̃  b  (b̂ â⁄ )a,  ̃     ̂. 
 
ã   , b̃   ̃    in the case that the two signals are not influenced by noise or 
disturbances (Robayo et al. 2010). 
 
Advanced control techniques such as SPC can successfully deal with variable time-
delay, nonlinearities, and input and output constraints (Kaya 2004). Since SPC relies 
on the availability of a patient model, it is important to provide accurate information 
to the controller in order to maximize its performance. In the case of anaesthesia, the 
TD varies between 40–180 seconds, and it is important that its value is known at all 
times and taken into account by the control strategy (Ionescu,  Hodrea & De Keyser 
2011). 
 
The PD function, which captures the effect dynamic, is modified in order to account 
for the time-delay that exists between the administration of the drug and the onset of 
effect. The anaesthesia sensor dynamics is now  a  distinct  part  of the  model,  
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which  allows other  sensing technologies to be used in conjunction with  the PD 
models identified using the  proposed  approach (Sreenivas et al. 2009). However, 
unless the time-delay dynamics are expressed as rational linear time invariant (LTI) 
transfer functions (e.g., using Pade approximation), the uncertainty related to the 
time-delay cannot be directly expressed as parametric uncertainty (Dumont, Martinez 
& Ansermino 2009). 
 
5.1.2 Identifying the PK time-delay 
Inter-patient   variability plays a important role in the overall system uncertainty 
(Bibian 2006).  For  example, there is a significant difference  in the PK  time  delay  
and  PD  time  constant  between  patients.   The time-delay cannot be directly 
expressed, unless the time-delay is expressed as a function of patient’s parameters 
such as the inverse of the effect-site compartment time constant (   ), the half-
maximal effective concentration (    ) and the steepness of the curve  .  While the  
     variability is more limited, its effect is still about 6-times difference in terms of 
the  overall  PK-PD   steady state  gain (Bibian 2006). In other words, the effects of 
the PD parameters have a significant influence compared with PK parameters. PD 
identification during induction, however, may not be practical due to a large number 
of factors that can affect the anaesthesia time course (Bibian 2006). Therefore, self-
tuning of  the  model  parameters  during  induction may  thus  be limited  to specific 
situations that  require trained human  operators  to  assess the  validity  of the 
identification data  and  the  derived  PD  parameters.   An alternative  to  a  full  
identification procedure  is  to  only  identify specific  PK-PD  parameters. Note that 
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the identification, when  identifying  the  PK time  delay,  directly translates  into  
significant  improvements  in  terms  of control performance (Muñoz et al. 2004). 
 
5.2 Smith Predictor and Controller Design 
The Smith Predictor Controller is able to compensate for the dead time through the 
use of the mathematical model of the process and its dead-time or time-delay to 
feedback to the primary controller, what the process variable would have behaved 
without the delay. In systems with large delays, performance can also be improved 
by using a Smith Predictor Controller structure that compensates for the nominal 
time-delay. This time-delay compensation allows an increase in the controller 
bandwidth, which results in improved performance. However, the performance of the 
Smith predictor largely depends on the accuracy of the process model. 
 
The Smith Predictor makes use of the nominal model of the system in order to 
compensate for the delay. See Figure 5.4. The zero-delay nominal model is simulated 
based on the same infusion rate that is entered into the system. As such, the model 
output represents the predicted delay-free response of the system. This response is 
then compared to the response with delay.   The result of this comparison is a signal 
that represents the future system response to the control action.  This signal is then 
added to the feedback signal.  As a result, the controller can be designed based  on a 
delay-free model,  which  results in added  stability in the control loop  that  can be 
further  used  to increase  the controller  bandwidth.   While the inherent limitation of 
a delayed system is still present,  the increased  control bandwidth  usually results in 
increased stability and better performances. 
 Chapter 5   Smith Predictive Control for Patient Model with Time-Delay  
 
   84 
 
Smith Predictive Controller
Patient
-
+R(s) +
-
DoA estimator of 
Time-delay
-DoA 
Time-
delay
Y(s)
 
Figure 5.4: The block diagram of Smith predictive control 
 
However, in systems presenting the large gain uncertainty, this technique potentially 
results in larger over-and under-shoots. For instance, if the gain of the nominal model 
is an order of magnitude different from that of the real system, the SPC structure may 
result in either under- or over-compensation, which is not desired. The SPC proposed 
a control structure to compensate for the time-delay shown in Figure 5.5. By using 
this structure, the effect of the time-delay in the system can be properly removed. As 
shown in Figure 5.5,       is the controller, the       denotes the transfer function 
of the patient without time-delay and  ̂     is the estimation model of DoA, t  is the 
time-delay of the patient response, and t  is the time-delay of measurement. The 
transfer function is obtained in the following equation:  
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Figure 5.5: The control system structure with the Smith predictor 
 
In Figure 5.5, the part with the dotted line is the SPC and its transfer function 
obtained as below: 
                                          
     
             ̂         
                                             
 
When  ̂           and   t  t  and then equation (5.9) becomes:  
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where        is the patient model and consist of two parts, PK and PD (Yelneedi, 
Samavedham & Rangaiah 2009). 
 
-
+
+
R(s)
D(s)
Y(s)
 
Figure 5.6 The equivalent block diagram by applying the Smith predictor 
 
We can see from equation (9.10) that the complicated transformation of the time-
delay will turn into two simple parts. One part is the transfer function of the system 
without the impact of the time-delay. The second part is just   the   simple   time-
delay. The equivalent block diagram of equation (9.10) is shown in Figure 5.6. Note 
that in the Figure 5.6, no exponential term exists and the value  of  the  system  is not  
affected  by  the  time-delay. Thus, the system will present the same closed-loop 
performance without the time-delay, only with the pure input time-delay tp.  The 
Smith Predictor Controller is used when DoA (the patient and instrumentation) time-
delays are significant as t = t .  
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5.3 Performance Evaluation in Simulation 
The study was performed on a data set of 12 patients of 20–50 years old. The data 
was obtained from reference (Yelneedi, Samavedham & Rangaiah (2009). The 
values for nominal patient obtained for the pharmacokinetics model were k10 = 
0.119, k12 = 0.112, k21 = 0.055, k13= 0.0419, k31= 0.0033, ke0 = 0.349, EC50= 
2.56,   = 2.5, as shown in Table 5.1. The adjustment of the controller gains was made 
in a simulation way trying to get a smooth transitory and a stable response. For 
validation purposes, a representation of the real BIS signal    “signal without time-
delay” was built. A time-delay  was added  to  the  simulator  in  order  to  represent  
the  delay introduced  by  the  BIS  monitor.  Thus, after several trials adequate 
values for SP Controller set values were tested in the whole population of the study. 
Figures 5.7, 5.8, 5.9 and 5.10 present the evolution of the anaesthesia for three 
different patients as shown in the simulation model in Figure 5.11. The controller 
parameters are adjusted depenging on  the  error  between  the  system  output  (BIS)  
and  the model  reference  output  defined  for  this  closed-loop.  
 
The SPC has to maintain BIS between 40 and 60 during the surgery. As well, it is 
very important to maintain the drug concentration within the acceptable limits in the 
patient’s body. The delay signal is then added to the feedback signal.  As  a  result,  
the controller based  on a delay-free  model,  which  results in added  stability in the 
control loop that can be further used to increase the controller bandwidth. As far as 
the implementation of the SP is concerned, the nominal time-delay is now replaced 
by the identified time-delay. 
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When a patient experiences significant time-delay, it is quite common to augment the 
controller with a Smith Predictor, a construction that removes the delay term from 
the characteristics polynomial of the closed loop. 
 
The current work shows that patient and instrumentation time-delays play an 
important role in controlling the depth of anaesthesia performance. In Figure 5.7, it is 
possible to observe the effect of the time-delay by applying the proposed algorithm. 
This improves the overall performance of the SPC controller compared with the 
performance of PID controller regarding overshoot, undershoot and settling time. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7: Smith predictor with nominated time-delay 
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In Figures 5.8, 5.9 and 5.10 an insensitive patient requires relatively more drug 
dosage and responds more slowly to the drug. For the sensitive patient, the nominal 
patient model predicts a lesser concentration than the actual concentration because it 
infuses fewer drugs based on the larger gain BIS response to Propofol infusions. It  
should  be  mentioned  here  that  the  novelty  of  the current  work  is  that  the  
time-delay model  can  be  used  for  different types of drugs. 
 
 
Figure 5.8: Smith predictor without time-delay 
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Figure 5.9: Smith predictor with time-delay for three different patients 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Smith Predictor with time-delay for two different patients 
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The configuration of this controller can be seen in Figure 5.11.  
 
Figure 5.11: Smith predictive control simulation’s block diagram 
 
Figures 5.12 and 5.13 present the performance of the SPC for the infusion rate of 
Propofol and the predicted plasma Propofol concentration. In this case, the adjustable 
parameters are the static gain and the time constant of the approximated first-order 
model used in the Smith Predictor. 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Performance of SPC for three different patients 
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Figure 5.13: SPC for three different patients 
 
5.4 Conclusions 
In this chapter, the SPC has been introduced to estimate the TD originated from the 
patient and instrumentation (BIS monitor). The TD estimation algorithm is tested on 
a data set of 12 patients. The obtained results show that the time-delays play an 
important role in the depth of anaesthesia control performance. This study agrees 
with similar studies reported in literature (Yelneedi, Samavedham & Rangaiah 
2009).  
 
The estimation algorithms are based on the Smith Predictive Control and have been 
improved with time-delay compensation modules that notably improve the 
performance of the overall patient response. These models have been implemented in 
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simulation using Simulink and Matlab Control Toolbox. The results have been 
compared to the control without compensator. In the system performance, the settling 
time has been shorted to 30% and the overshoot and undershoot have been reduced 
by about 15%. To make the strategy applicable to different patients an adaptive 
scheme has been designed so that the controller adapts the algorithm to the dynamics 
of the specific patient. Also to further improve the system response the accuracy of 
the system model for DoA needs to be improved further.  
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CHAPTER 6  
 
ROBUST DEADBEAT CONTROL 
FOR PATIENT MODEL WITH 
UNCERTAINTIES 
 
 
6.1 Uncertainties and Disturbances in DoA Control 
More recently, considerable efforts have been made to identify and control systems 
with uncertainty and nonlinearity in medical related control system. Westenskow 
(1997) developed a closed-loop PID controller to control the depth of anaesthesia. 
Sakai et al. (2000) employed a closed-loop PID control system for Propofol 
administration using BIS (Bispectral Index) as the controlled variable.   Both of them 
concluded that their systems provided intra-operative hemodynamic stability and a 
prompt recovery from the sedative-hypnotic effects of Propofol. Absalom et al. 
(2002) developed a similar closed-loop PID controller using BIS as the controlled 
variable, and a Propofol targeting central plasma concentration-controlled infusion 
system as the control actuator. The authors concluded that further studies were 
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required to determine if control performance could be improved by changing the 
proportional gains of the PID controller or by using an effect-site-targeted Propofol 
controlled infusion system. Later, they modified their control algorithm to a target-
controlled infusion (TCI) system that regulated effect-site concentration, and proved 
it more efficient.  However, PID controllers still faced some stability problems 
(Absalom & Kenny 2003). 
 
This study applies the deadbeat robust control technique to the depth of anaesthesia. 
First, a DoA model is build up based on the literature review. This model is a single-
input-single-output (SISO) system with nonlinear component. Then, a PID-based 
robust deadbeat control scheme is applied to the SISO systems, and a deadbeat 
controller is designed. The robust deadbeat controller can tolerate system parameter 
uncertainty for up to  50% (Dawes et al. 1994). The additions of the extra gains 
permit the designer more flexibility for making any plant work with this method. 
This feature is used to deal with the uncertainty of the DoA model. The proposed 
method is implemented and evaluated in simulation. Compared with the other two 
different PID based control systems, the proposed method has less over and 
undershoot, shorter settling time and is more robust to parameter change caused 
disturbances.  
6.2 Patient Model with Uncertainties  
First we consider  the  drug  modeling approach and how  the  administered  drug  
distributes  around  the  body.  This step leads to a pharmacokinetic model (PK) 
which can be used to predict the blood plasma concentration of the drug (Alonso, 
Lemos & Mendonca 2008). The second step is the mathematical expression related 
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to concentration of the drug effect itself. This expression is referred to as 
pharmacodynamic model (PD) (Bibian 2006). 
 
Pharmacokinetics is the study of the absorption, distribution, metabolism and 
elimination of drugs by the body (as shown in Figure 6.1). The pharmacokinetic  
model of a drug is  a  mathematical  term  relating  to the  drug  blood plasma  
concentration          to  the  administered  dose      .  The aim of this section is 
thus to define the transfer function of      : 
 
                                                            
     
    
                                                                     
 
 
K e0
(Propofol) 
Infusion rate 
K 10
K 13K 21
Compartment 1
K 12 K 31
Metabolism Effect Site
Compartment 3Compartment 2
1V
2
V
3
V
 
Figure 6.1: The pharmacokinetic model 
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The PK  can be expressed as  a  time  course  of  the  concentration  of  any given  
drug  within  the  plasma  and  other  tissues  of the  human  body. Throughout  the  
absorption phase  following  an  intravenous  bolus  administration,  the  anaesthetic 
(Propofol)  mixes  quickly within  the  central  blood  pool, resulting  in  a  plasma  
peak  concentration (Bailey & Haddad 2005). A delay elapses between the actual 
injection of the anaesthetic (Propofol) and its mixing within the blood pool. Systemic  
circulation then  distributes  the  anaesthetic  to  a  variety  of  tissues  within  the  
body (Alonso, Lemos & Mendonca 2008). 
 
The time course of the concentration for most  drugs, within the blood plasma after 
the intravenous administration and uptake can be fitted to resemble a decaying 
function,  with  two  distinct  modes  corresponding  to  the  distribution  and  
elimination  phase  respectively. This behaviour can be expressed mathematically as: 
 
                                  t   e
     e                         ⁄                                 (6.2) 
 
where     t   is  the  drug  plasma concentration  expressed  in  microgram  per 
millilitre (Propofol),   is the rate constant of the distribution phase,   is the  rate 
constant  of the  elimination phase. 
 
In many cases, a tri-exponential model will capture the kinetics of the drug much 
better (Alonso, Lemos & Mendonca 2008). 
 
                        t   e
     e     e                         ⁄                             (6.3) 
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where   and   describe  the   fast  dynamics  corresponding  to  the   distribution  
phase. 
 
A main advantage of exponential models is that they can be simply derived using 
graphical means. The identification can be carried out directly by using either bolus 
data or analysing the decaying blood plasma characteristic, or by using infusion data 
and analysing how the plasma concentration increases over time (Alonso, Lemos & 
Mendonca 2008). 
 
In   terms of control and system engineering, the exponential model in equation (6.3) 
can be directly expressed as: 
 
                                   
     
    
 
 
     
 
 
     
 
 
     
                                 
 
The total amount of the anaesthetic delivered into compartment one (   ) is 
eliminated according to the rate constant    . The anaesthetic is distributed in the 
other two compartments (      ) at a rate of     and    . The concentration of    
decreases quickly whiles the concentrations of    and     increase. Once the 
concentrations in compartment one and any of the peripheral compartments (      ) 
attain and reach equilibrium, the distributive process setback and the anaesthetic 
stored in the peripheral compartment returns to the central compartment at the rate of 
    or    . Because the blood of compartment one acts as a transporter for the 
anaesthetic, there is no direct exchange between the two peripheral compartments. In 
other words, only the anaesthetic presents in compartment one can be eliminated 
(Bibian 2006). 
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The mathematical expressions in a state space representation can be obtained by 
writing the mass balance equations in (6.5) and (6.6): 
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]                                                 (6.6) 
 
where      is the  volume of  compartment one.   Also, by definition,  the  plasma 
blood concentration equals  the  drug  concentration  of compartment one,  i.e.,  
   t     t . 
 
In  order  to  simplify  the       model  as  a  SISO  transfer   function using both  
the  exponential and  compartmental  parameters as in equation (6.6) 
(GentiliniRossoni-Gerosa, et al. 2001): 
 
                                         
     
    
 
              
                 
                                  
 
The  function  of  the PD  model is  to  mathematically  express  the  observed  effect  
of  a  drug  as  a low-pass filter  is  used  to  relate  the  Propofol  plasma  
concentration as shown in Figure 6.2 (Alonso, Lemos & Mendonca 2008): 
 
 Chapter 6   Robust Deadbeat Control for Patient Model with Uncertainties 
 
   100 
 
                                                               
    
    
                                                                   
where        is the  pharmacodynamic  model  and       is the  drug  effect. 
 
The  effect-site  concentration  is  related  to  DoA  as  Hill equation (Dumont, 
Martinez & Ansermino 2009). 
 
                                            [
  
    
   
         
  
]                                                 
 
The mathematical expression of the effect site drug concentration        is a function 
of the plasma concentration       as in equation (6.10): 
 
                                                  [
   
       
]                                                               
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Figure 6.2: The pharmacodynamic model 
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6.3 Robust Deadbeat Control (RDC) Technique 
Figure 6.3 shows the basic structure of the robust deadbeat control system, and Table 
6.1 is   the deadbeat controller coefficients and response times. This technique 
initially works only for lower-order plants (Wen & Lu 2008).  If a higher–order plant 
system is considered, then there is a need for higher gain. In this design, the 
controller could cope up to 50% variations and uncertainties in plant parameters 
(Dawes et al. 1994). With changes in patients’ PK and PD parameters (   ,    ,    ,. 
    ,   and     ) from 10% to  20%, 30%, 40% up to 50%, the robust deadbeat 
controller is still able to tolerate the changing parameters. 
 
The deadbeat controller design and derivation method utilizes the following 
procedures. First, using a PID controller as      , and then adding a cascade gain K 
before the PID controller. Second, add a state variable feedback gain   , that will 
make the system over-specified by at least one variable. Third, determine the number 
of poles for       , where n  equals the number of poles in       . Refer to the 
Figure 6.3 feedback H(s) depending on the number of poles in       . The following 
steps are involved with this method: 
1. H(s) = 1 for np = 2 
2. H(s) = 1 +Kbs for np = 3 or 4 
3. H(s) = 1 +Kbs + Kcs
2
 for np = 5 
Then select gains, using the coefficients from Table 6.1, to achieve the deadbeat 
response with the following requirements:  
4. Set K = 1 
5. Set    =   
 /(80% of the desired settling time) 
6. The characteristic equation of the closed loop transfer equation will be equal to:  
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7. The root of H(s) must be real and negative 
8. The smallest root of H(s) will set the desired settling time by   the relationship: 
[4/ (smallest root)] and be approximately equal to the desired settling time. 
 
Then increase K until the response becomes deadbeat and the settling time is 
approximately equal to the desired value. 
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Figure 6.3: Robust deadbeat control structures 
 
Table 6.1: Deadbeat coefficients and response times 
Order                  
    
  
2nd 1.82    3.47 4.82 
3rd 1.90 2.20   3.48 4.04 
4th 2.20 3.50 2.80  4.16 4.81 
5th 2.70 4.90 5.40 3.40 4.48 5.43 
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The design procedure of a PID-based robust deadbeat control is shown below, taking 
fourth-order       and fifth-order       systems as examples 
 
                                      
  
 
                    
       
                               
and  
 
                      
  
 
                    
            
  
                              
 
 
For equations (6.11) and (6.12), the coefficients  ,  ,   and   are selected from Table 
6.1. Taking the fourth-order system first as an example and then using the same 
procedure with fifth-order system with a desired settling time       , from Table 6.1 
the normalized settling time can be found as: 
   
    
  
 
 
Therefore    can be found as: 
   
    
    
        
 
The characteristic equation of the closed-loop transfer function of the forth-order 
systems is: 
 
 
       
     
       
     
  
 
From Table 6.1,  ,   and   can be found as: 
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The transfer function of the forth-order systems is: 
 
      
          
                                           
 
 
 
To apply the deadbeat technique to the DoA model, first comparing the characteristic 
equation in equation (6.11), with the characteristic equations of different patients. 
6.4 Applications of RDC to DoA Control 
The block diagram of the DoA designed system is depicted in Figure6.4. 
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Figure 6.4: Robust deadbeat control structure for DoA 
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The closed-loop control function for the DoA model can now be written as: 
 
    
    
 
          
                            
 
 
 
Then, use the technique initially proposed by Dorf et al. (Dawes et al. 1994), to 
determine these parameters.  The characteristic equation of the above transfer faction 
is equal to the characteristic equation of the deadbeat transfer function. By using the 
characteristic equation of the deadbeat transfer function to obtain the characteristic 
equation of the closed-loop transfer function of DoA as: 
 
       
     
       
     
  
 
From Table 6.1,  
                       
 
   
  
 
    o  the de i ed  ett in  ti e    
 
 
The desired settling time for DoA is 6 minutes, then    can be found as: 
   
  
 
        
 
    
        
        
Therefore the characteristic equation now can be written as: 
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Let   equal 1, and then by compare the characteristic equation to find the variables 
as: 
        
            
   
 
                                      
 
Increase   until the response becomes deadbeat and settling time becomes 
approximately to the desired value. 
6.5 Simulation and Results 
The proposed control schemes were implemented and evaluated, using Simulink and 
Matlab Control Toolbox, to thoroughly investigate the system performance. 
 
Figure 6.5 shows the implementation of the deadbeat DoA control system. 
 
 
Figure 6.5: Implementation of a robust deadbeat control structure for DoA 
0.040382(s+0.025992)(s+0.0018266)
(s+0.378910)(s+0.005896)(s+0.0012622)
Patient Model
PID
PID Controller
Output 
-K-
KInput
-K-
H2(s)
In1Out1
H1(s)
 Chapter 6   Robust Deadbeat Control for Patient Model with Uncertainties 
 
   107 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: DoA robust deadbeat control response 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: DoA robust deadbeat control response for different values of K 
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Figure 6.8: Comparison of the performance of the deadbeat with IMC and PID 
controllers’ 
 
Figures 6.6 and 6.7 show the responses of DoA system in different situations, in 
other words the values of K are changing from 1 until the system reaches a better 
response. For example, in Figure 6.7 K equals 2, 2.5 and 7.23. It is clear that all the 
responses settle and reach the desired positions with the time frames. While, there is 
overshoot, the system responses still meet with all the requirements and 
specifications. 
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Figure 6.8 shows the response of a traditional PID control for DoA. The parameters 
of the PID controller for DoA are    =1000,   = 10 and   =32. Comparing Figure 
6.7 and 6.8, it is clear that the robust control performance is far better that the 
traditional control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: DoA deadbeat control response for different patients 
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performance is much better that the IMC, where the settling time is approximately 
eight minutes for IMC and  about 4.3 minutes for  the robust deadbeat control. 
 
The deadbeat design can tolerate system parameter changes to about 40% without 
degrading system performance.   Figure 6.10 shows the responses after changing the 
model parameters form 10% to 20%, 30%,  0% and 50%. As a result the system’s 
response remains almost unchanged when all the plant parameters vary by as much 
as 40%. The  response  of  the  system  with  no  plant  variations and  then  with  
40%  of plant  parameter variations, is acceptable.  
 
Figure 6.10: DoA deadbeat control response for changing patient parameters 
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6.6 Conclusions 
This study investigated a PID-based robust deadbeat control technique in DoA 
control. The technique was originally designed to suppress system parameter 
uncertainties. We applied this technique to accommodate the inter-patient differences 
for DoA control  
The proposed method was implemented and evaluated in simulation using realistic 
data. The results are compared with the results obtained using two other methods. 
The results show that the proposed robust deadbeat control scheme performs better 
both in overshoot/undershoot and settling time. The system settling time has been 
reduced to 1.5 minutes and the over and undershoot has been shorted about 15%. To 
investigate the robust capacity, we have changed the system parameters from 10% to 
20%, 30 %, 40% and 50%. The results show that the proposed method can tolerate 
about a 40% change in parameters. In addition, the robust deadbeat control scheme is 
easier to design and does not need any complicated math calculations except the 
normalisation of the coefficients table. 
 
 
 
 
 
 
 
 
 
 Chapter 7   Model Predictive Control of DoA  
   112 
 
CHAPTER 7  
 
MODEL PREDICTIVE CONTROL 
OF DOA 
 
 
7.1 Model Predictive Control Technique 
Model Predictive Control (MPC) has been recognised, in process control, as a proven 
technology   capable   of   dealing   with   a   wide   range   of multivariable 
constrained control problems.  Nevertheless, most industrial controllers are based on 
linear internal models, which limit their applicability. 
 
This chapter demonstrates the control of hypnosis using Model Predictive Controller 
and compares its performance with PID and IMC approaches. 
 
In clinical anaesthesia, automatic regulation in a closed-loop control of infusion of 
drugs, has been shown to provide more benefits when compared to manual 
administration (Abdulla & Wen, 2011; Abdulla & Wen, Peng 2011; De Keyser & 
Ionescu 2003; Gentilini, et al. 2001; Sreenivas, Lakshminarayanan & Rangaiah 
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2007). A well-designed model predictive control system can avoid both the over-
dosage and under-dosage of drugs. Closed-loop control minimizes drug 
consumption, intra-operative awareness and recovery times, thereby decreasing the 
cost of surgery and the cost of postoperative care. Overall, this improves the patient’s 
safety during surgery and rehabilitation after the surgery. 
 
Absalom et al. (2003) produced a closed-loop control system of anaesthesia that uses 
BIS as the control variable to automatically control the target blood concentration of 
Propofol (Target Controlled Infusion (TCI) system). The system was able to provide 
clinically sufficient anaesthesia in all patients, with enhanced accuracy of control. 
There was a tendency for more accurate control in those patients in whom the control 
algorithm incorporated effect-site steering (Absalom & Kenny 2003; Engdahl et al. 
1998). A method and an algorithm are proposed for controlling the effect site 
concentration using a TCI method. The method limits the peak plasma concentration, 
thereby slowing the start of anaesthetic drug effect but potentially improving side 
effects. Simulation is used to observe the delay in time to peak effect for five types of 
anaesthetic drug when the peak plasma concentration is limited by the algorithm; the 
control system was evaluated in 30 patient cases. This study clearly suggests the 
desirability of individual tuning of the controller parameters. 
 
A method for an enhanced tuning of the PID controller parameters to the patient’s 
individual dynamics was presented by Mendonca & Lago (Mendonca & Lago 1998). 
Auditory Evoked Potentials (AEP) has been reported to accomplish many 
requirements for measurement of the level of anaesthesia. A development has been 
made to this system to obtain a single index which presents the morphology of the 
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AEP and uses this index as the input signal for closed-loop anaesthesia during 
surgery in patients who did not receive neuromuscular blocking drugs (Kenny & 
Mantzaridis 1999). A robust control of depth of anaesthesia was developed by 
Dumont et al. (2009) to design both robust and PID controllers based on fractional 
calculus to control the hypnotic state of anaesthesia with intravenous management of 
Propofol (Dumont, Martinez & Ansermino 2009). The objectives of these controllers 
are considered to compensate for the patient’s inherent drug response variability, to 
accomplish good output disturbance rejection, and to achieve good tracking to set 
point response (Ejaz & Jiann-Shiou 2004). The infusion and the drug effect are 
represented by the pharmacokinetic and pharmacodynamics models (Bressan et al. 
2007). 
 
A model based on a compartmental approach is used. In each compartment, the drug 
concentration is homogeneous and there are exchanges between compartments. A 
three compartments model is used, in which the main compartment represents 
intravascular blood (blood within arteries and veins) and highly irrigated organs 
(such as heart, brain, liver and kidney). The two other compartments represent 
muscles, fat and other organs or tissues. The PK consists of a 3-compartment model 
shown in Figure 7.1. 
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                                                                                                               (7.3) 
 
                                                                                                                       (7.4) 
 
where    represents the amount of drug in the central compartment,    and    denote 
the amount of the drug in compartments two and three, respectively. Also    is equal 
to 
   
    
 and    is equal to 
 
    
. The constants     represent the transfer rate of the 
drug from the i    compartment to the      compartment. The constant     is the rate 
of the drug metabolism and   is the infusion rate of the anaesthetic drug into the 
central compartment. 
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Figure 7.1: Compartmental model of the patient 
 
 Chapter 7   Model Predictive Control of DoA  
   116 
The pharmacodynamics is characterized by a low-pass filter related to the central 
compartment concentration     in blood: 
 
                                          ̇                                                            (7.5) 
 
 
where     and     are constants and    is the amount of drug in the effect 
compartment and    is the plasma Propofol and and Remifentanil concentrations. 
 
                                                    
   
       
                                                                 
 
where      is the inverse of the effect-site compartment time constant and      is the 
half-maximal effective concentration.   is a steepness of the concentration response 
relation. 
 
The effect-site concentration is related to depth of anaesthesia (DoA) as  (Hill 
equation) (Munson & Bowers 1967): 
 
                                        t         [
  
 
    
    
 ]                                                     
 
where    represents the baseline value (conscious state without Propofol), which is 
typically set to 100;      denotes the maximum effect achieved by the drug infusion; 
     is the drug concentration at half maximal effect and denotes the patient’s 
sensitivity to the drug; and   determines the steepness of the static nonlinearity. 
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7.2 Model Predictive Control Design 
The fundamental objective of MPC as shown in Figure 7.2 is to determine the 
sequence of M future control policy (manipulated variable changes) so that the 
sequence of P predicted values (output variables) has minimal set-point tracking 
error (Shridhar & Cooper 1997). The  main purpose  of  the  non-linear  model  
predictive  control is  to find  the  future  optimal  drug infusion sequence in order to 
minimize a function based on a desired output trajectory over a prediction horizon to 
adjust the amount of medication given to improve recovery from anaesthesia 
(Yelneedi, Lakshminarayanan & Rangaiah 2009). The cost function is the integral 
over the squares of the residuals between the models predicted outputs y and the set 
point values r over the prediction time. 
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Figure 7.2: Model predictive control scheme 
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where, r is the set-point of the target for the BIS, u is the controlled variable, the 
Propofol infusion rate (       ) given in [mL/h], y is the output, the DoA level 
given in [%], d is the disturbance (d    
    ), the Remifentanil effect concentration 
given in [µg/mL], and d    
    
 is the Propofol effect concentration given in 
[µg/mL]. 
 
Model Predictive Control (MPC) is currently the most accepted method for handling 
disturbances predicting and estimating changes (Jonker et al. 2005). MPC plays an 
important role in solving such complex problems. The main elements of the method 
are plant model, constraints and objective function, as shown in Figure 7.3. The 
objective function is evaluated and the selection of controller is repeated until the 
optimum is obtained (Bequette 2007). 
 
u
u
K-1K-2K-3K-4 K K+1 K+M-1K+3K+2 K+P
Set point
Control horizon, M
Prediction horizon, P
Past      Future
y
yˆ
Set point
Past control action
Future control action
Predicted output
Past output
 
Figure 7.3: The basic concept of model predictive control 
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The technique requires solution of optimization problem at every sampling time, 
other constraints on the drug infusion can be added, such as, that the drugs (propofol) 
rate  are to remain constant during the last numbers of steps. A linear or quadratic 
cost functions will be used. Stability results are obtained on the same idea as made 
for linear systems. One or several of the following assumptions are made, terminal 
equality constraints, terminal cost function, terminal constraint set and dual mode 
control (infinite horizon): begin with MPC with a terminal constraint set, switch then 
to a stabilizing linear controller when the region of attraction of the linear controller 
is reached (Weber et al. 2004). Generally, an MPC algorithm consists of applying a 
control sequence that minimizes a multistage cost function. A typical formulation is 
 
                                   ∑ e 
  e  ∑    
     
     
   
   
                                        (7.8) 
 
Subject to: 
 
                     o  i                        
                                  o  i
                      
 
where, M and P as the lengths of the prediction and control horizons, Q and R are the 
weighting matrices for both BIS and input rate respectively. 
 
These Q and R can be used to tune the MPC controller to achieve the desired value 
between output performance and manipulated variable movement. 
 
MPC controllers are based on an optimal control problem.  Therefore, the weights 
used in the cost function should be determined. Another cost function for the MPC 
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block in MATLAB (see equation (7.9)) has been used to improve the drug infusion 
during surgery (Cardoso & Lemos 2008). 
 
          
       (          )
 
  
 (          )        
    
   
                                                                                                                          (7.9) 
 
where,    is a diagonal matrix representing the input weight,     is a diagonal 
matrix representing the input rate weight,   is a diagonal matrix representing the 
output weight,                        
    is the vector of values of the control signal 
over the control horizon,               
      
              
      
    is the vector of values 
of the desired control signal over the control horizon,                         
   is 
the vector of values of the rate of the control signal over the control horizon, 
                      
  is the vector of values of the output over the prediction 
horizon,                       
   is the vector of values of the reference over the 
prediction horizon,    is the weight factor on the slack variable (used to penalize the 
violation of the constraints), and   is the slack variable, a variable to turn the 
inequality into an equation, it allows the constraints to be violated by a certain 
amount. 
7.2.1 Constraints 
The range of DoA signal is between 0 and 100% (initial signal is about 97.7%) and 
the Propofol infusion must be at a positive rate (a negative rate would mean that 
propofol was being taken from the patient). These constraints are summed as shown 
in Table 7.1. 
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Table 7.1: Model predictive controller constraints 
Variables Minimum Maximum 
   
  
 
  
0   
  
  
 
  
  
  
      
        0 100 
 
In reality, these are the basic constraints. The maximum drug infusion rate and the 
changes in the medication infusion rate are constrained by the apparatus and 
equipment, but these bounds are very high and are never reached in practice. 
7.2.2 Time horizons 
The prediction horizon P has been chosen based on open-loop settling time, whereas 
control horizon M is chosen based on the value between faster response (large value 
of M) and robustness (small value of M).  Therefore, the chosen value for M is very 
small, compared to P.  To reject the disturbances that are due to patient-model 
mismatch, the patient model is augmented by the output disturbance model, which is 
an integrator that is driven by white noise. 
 
The MPC parameters are output (BIS) weight, Q = 1; input rate (Propofol) weight, R 
= 0.8; prediction (output) horizon, P = 30; and control (input) horizon, M =3. These 
parameters have been chosen by using direct search optimization for hypnosis 
regulation. 
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7.2.3 The simulation model of MPC  
The main tuning parameters are the control and prediction horizons (M and P) and 
the weight applied to manipulated and control variables. 
 
The prediction horizon determines the amount of predictions that are used in the 
optimisation calculations. Increasing the prediction horizon results in more 
conservative control action that has a stabilising effect, also increases the 
computional efforts (Yelneedi, Samavedham & Rangaiah 2009). A very large 
predication horizon recommended only for a very good model and if feedback is 
limited. 
 
The control horizon determines the number of future control actions that are 
calculated in the optimisation step to minimise the predicted errors. A large number 
for the control horizon, relatively to the prediction horizon, tends to too much control 
actions, but small value for control horizon leads to a robust controller. 
 
The model predictive control simulation design shown in Figure 7.4, the patient 
model has been used to estimate the value of the output variable BIS. The difference 
between the measured BIS from the process model and the model output, serves as 
the feedback signal to the prediction part. With this model output and input variable, 
the predction part estimates the future values of the output BIS. Base on the predicted 
BIS values, the MPC controller calculates the future input moves of which only first 
input move is implemented by the controller at current sampling instant. 
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Figure 7.4: The model predictive control simulation design 
 
7.3 Results and discussion 
A Model Predictive Control system of Propofol and Remifentanil is constructed. The 
time that the BIS reaches the range of 50 ± 10, is called the settling time for the BIS 
during general anaesthesia. The specifications of the MPC system for the settling 
time range was between 5 and 10 mintues and the robutness was stable for all 
parameters obtained in the simulation results and is shown in Figure 7.5. 
The target value of BIS is between 60 and 40. Figure 7.5 shows a simulation result 
for a subject with the nominal parameters. The MPC system can maintain BIS at the 
relevant target levels and the settling time is within ten minutes. 
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Figure 7.5: The performance of the MPC for nominal patient 
The predicted plasma Propofol concentration (  
    
) has to be between 0.5 µg/ml 
and 5 µg/ml because it is the clinically accepted range (Absalom, Sutcliffe & Kenny 
2002) that is not measured but estimated using the nominal patient model. 
The manipulated variables    (propofol infusion rate) is constrained between 0 and 
20         (Furutani et al. 2005; Sawaguchi et al. 2008). 
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The tuning of the MPC design for the nominal patient’s data for DoA parameters 
shown in Table 7.2. The MPC tuning parameters are M, and P, the input horizon and 
the prediction horizon respectively; Q and R, weighting coefficient for BIS and the 
weighting coefficient for the Propofol rate respectively. MPC controller performance 
for different tuning weights on the output variables and input variable rates for 
insensitive patients are shown in Figure 7.6. 
Figure 7.6: MPC controller performance for different R and Q weights 
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Table 7.2: Nominal patient’s data for DoA parameters (Marsh et al. 1991; Minto, 
Schnider & Shafer 1997) 
Variable Default value Unit 
vc 0.228 [L/kg] 
    0.119     
    
    0.112     
    
    0.0419     
    
    0.055     
    
    0.0033     
    
    0.25     
    
    
     11.20 [µg/mL] 
    
    
 2.65 [µg/mL] 
   97.7 [%] 
  2.561  
 
The performance of MPC, IMC and PID for sensitive patients for the set-point 
tracking during the surgery period is shown in Figure 7.7. These three controllers 
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(MPC, IMC and PID) are able to meet performance specifications in spite of the 
significant and reasonable variation in the model parameters such as inter-patient 
variability based on PK-PD model. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.7: The performance of MPC, IMC and PID controllers for sensitive patient 
 
There is a variation in PK (based on age and weight) and PD (patient’s sensitivity to 
the drug) model parameters.This assumption is based on the inter-patient and intra-
patient variability (Schnider et al. 1999). The PK variation is about 25% of the 
model’s parameters. In addition, simulation studies showed that the variability in PD 
parameters have more impact on BIS than the variability in PK parameters (Schüttler 
& Ihmsen 2000). 
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The simulations results show that an insensitive patient requires relatively more 
Propofol and Remifentanil dosages and responds slowly to those drugs (as shown in 
Figure 7.8 for four different insensitive patients from Table 7.3 and 7.4). 
 
Table 7.3: Patient PK-PD parameters for Propofol used in this study (Niño et al. 
2009) 
Patient                                
1 (sensitive) 0.08925 0.084 0.06875 0.031425 0.004125 1.6 0.459 2.000 
2 0.14875 0.112 0.06875 0.031425 0.002475 2.65 0.459 2.561 
3 0.11900 0.112 0.05500 0.041900 0.003300 2.65 0.239 2.000 
4 0.14875 0.140 0.04125 0.052375 0.004125 1.60 0.239 2.000 
5 0.08925 0.084 0.06875 0.031425 0.002475 3.70 0.239 3.122 
6 (Nominal) 0.11900 0.112 0.05500 0.041900 0.003300 2.65   0.349 2.561 
7 0.14875 0.140 0.04125 0.052375 0.004125 3.70 0.349 2.561 
8 0.11900 0.112 0.05500 0.04190 0.003300 2.65 0.239 2.000 
9 0.08925 0.084 0.04125 0.052375 0.002475 3.70 0.239 3.122 
10 0.08925 0.084 0.06875 0.031425 0.002475 3.70 0.239 3.122 
11 0.11900 0.112 0.05500 0.041900 0.003300 2.65 0.239 2.561 
12 
(Insensitive) 
0.14875 0.140 0.04125 0.052375 0.00247 3.70 0.239 3.122 
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Table 7.4: Patient PK-PD parameters for Remifentanil drug used in this study (Niño 
et al. 2009) 
Patient 
 
    
 
    
 
    
 
    
 
    
 
     
 
    
 
  
 
1 (sensitive) 0.38175 0.2715 0.24375 0.00975 0.0175 7.840 0.6708 1.757 
2 0.50900 0.3620 0.24375 0.01625 0.0105 7.840 0.6708 1.757 
3 0.63625 0.2715 0.24375 0.01300 0.0140 7.840 0.6708 1.757 
4 0.63625 0.2715 0.24375 0.01300 0.0140 7.840 0.6708 1.757 
5 0.63625 0.2715 0.24375 0.01300 0.0140 7.840 0.6708 1.757 
6 (Nominal) 0.50900 0.3620 0.19500 0.01300 0.0140 11.20 0.5160 2.510 
7 0.50900 0.3620 0.19500 0.01300 0.0140 11.20 0.5160 2.510 
8 0.50900 0.3620 0.14625 0.00975 0.0140 14.56 0.5160 1.757 
9 0.63625 0.2715 0.14625 0.01625 0.0175 11.20 0.5160 1.757 
10 0.38175 0.3620 0.19500 0.00975 0.0105 11.20 0.3612 1.757 
11 0.50900 0.2715 0.14625 0.00975 0.0105 14.56 0.3612 2.510 
12 
(Insensitive) 
0.63625 0.4525 0.14625 0.01625 0.0105 14.56 0.3612 3.263 
 
Based on the PD parameters, changing the results shows that the higher      
indicates the need for more Propofol and Remifentanil drugs to get the same 
hypnosis and analgesia levels. Also higher   (3.122) indicates higher non-linearity, 
and lower     (0.239) represents a slowness in response. 
 
A sensitive patient requires less drug dosage to get the same hypnosis and analgesia 
levels. In PD parameters, lower      indicates that less Propofol and Remifentanil 
are required to get the same level of hypnosis and analgesia. The lower amount of  , 
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represents weak non-linearity in the system response. Higher amount of     indicates 
a quicker response. 
Figure 7.8: The performance of MPC controllers for four insensitive patients 
 
Figures 7.9 and 7.10 show the performance of the MPC for sensitive patient is faster, 
drug usage is less, and that the response for the insensitive patient is sluggish and 
drug usage is high compared to the response of the nominal patient. 
The performance of the three controllers (MPC, IMC and PID) is checked for the 12 
patients, the insensitive, nominal and sensitive patients.  
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Figure 7.9: The performance of MPC controllers for sensitive patient number 2 
 
 
 
 
 
 
 
 
Figure 7.10: The performance of MPC controllers for sensitive patient number 4 
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The Simulink model structure can be seen in Figure 7.11. 
 
 
Figure 7.11: The Simulink model structure 
 
Figure 7.12 depicts the responses of IMC and PID controllers for disturbances in the 
BIS signals for the insensitive patient. Figure 7.13 shows the MPC performance of a 
sensitive patient at a set point of 50 and the controller maintained the BIS within the 
operating range in spite of noise in the signal. It can clearly be concluded that the 
performance of the MPC is better than that of IMC and PID controllers. The average 
control effort with MPC is higher compared to IMC and PID controllers. At this 
point, larger disturbances cause higher valve movement leading to a higher control 
effort with MPC. These disturbance effects dominate the effect of noise in BIS signal 
which mostly affect the performance and control effort of IMC and PID compared to 
MPC. 
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Figure 7.12: The performance of IMC and PID controllers for insensitive patient 
 
 
 
 
 
 
 
 
 
Figure 7.13: The performance of MPC controllers for sensitive patient number 3 
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7.4 Conclusions 
The automatic induction of anaesthesia drugs has more advantages when compared 
to the manual administration of other drugs. In this chapter, a model predictive 
control strategy has been developed for automatic regulation of hypnosis and 
analgesia using BIS as controlled variables. The controllers were designed based on a 
nominal patient model, and then tested for their effectiveness, ability and robustness 
on 12 patient parameters covering sensitive to insensitive patients and operating 
conditions by the use of Simulink simulation. The results show that the MPC 
controller is capable of improving Propofol and Remifentanil inductions by 20 to 
25% compared to PID controller, 8 to 10% compared to The IMC, and better 
robustness in set-point tracking and disturbance rejection when implemented on 
different patient parameters. In addition, the MPC control scheme is easier to design 
and does not need any complicated mathematical calculations. 
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CHAPTER 8  
 
CONCLUSIONS AND FUTURE 
WORK  
 
 
8.1 Review of Research 
This dissertation described the contemporary developments of depth of anaesthesia 
control techniques and human body model. Five advanced controllers were proposed 
and thoroughly investigated for the closed-loop administration of hypnotics and 
analgesic medications. The results demonstrated their clinical feasibility on patients 
undergoing general anaesthesia. 
 
Compartmental-based human body models aim to imitate drug distribution based on 
assumptions regarding drug binding, blood flow to the different body compartments 
and their respective volumes. These assumptions are based on measurements. The 
human body model parameters are generated by scaling the corresponding animal 
models. Mamillary compartmental models on the other hand are based on input-
output data sequences. The synthesis of the advantages of both model concepts 
allows the description of a precise input-output behaviour. The derived model is 
adequately descriptive for control purposes. 
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8.2 General Conclusions 
Chapter 3 studied the human models and the model development for hypnotic and 
analgesic. The description of the kinetics and dynamics of human body model were 
investigated. The pharmacokinetics and phrmacodynamics parameters variations in 
patient model to account for patient-model mismatch were also dicussed. Infusion of 
the anaesthetic to the detection of DoA using BIS includes considerable time-delays. 
The effects of the time-delay and time-delay model were analysed in this chapter. 
Two uncertainties in PK-PD modeling and their  effects   were investigated. The first 
uncertainty is caused by intra-patient variability, and the second is the uncertainty 
originating from  inter-patient  variability. 
 
The IMC control of depth of anaesthesia using BIS as the controlled variable 
investigated in Chapter 4. The performance of the internal model controller was 
compared with that of the conventional PID controller. The IMC was found to be 
more robust to inter-patient variability and disturbances rejection compared to the 
PID controller. The proposed IMC control has no undershoot. The proposed IMC 
strategy was also found to be more robust to intra - patient variability. 
 
Chapter 5 studied Smith Predictive Control and the effects of time-delay on depth of 
anaesthesia. This chapter investigated the impact of the time-delays of the patient and 
instrumentations such as the BIS monitor used in a closed-loop depth of anaesthesia 
control system, and proposed to apply the Smith Predictive Technique to identify and 
compensate the time-delay. The proposed method was evaluated using measured BIS 
signals in simulation. Extensive simulations were conducted using Simulink to test 
the performance of the SPC controller for robustness, set-point tracking, and 
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disturbance and noise rejection characteristics. The results showed that the proposed 
procedure improved the performance of the closed-loop system for reference 
tracking and overall stability. The proposed method also has about 15% less 
overshoot, is two minute shorter in settling time and is more robust to disturbances. 
 
A robust deadbeat controller for patient model with uncertainties was investigated in 
Chapter 6. In this depth of anaesthesia control system, the model includes nonlinear 
parts. The proposed method applied a deadbeat control technique and developed a 
robust control method. The proposed robust control system with a deadbeat 
controller was evaluated in simulation. The results showed that the proposed robust 
deadbeat control scheme performs better both in overshoot/undershoot, and settling 
time. The system settling time is reduced to 1.5 minutes and the overshoot and 
undershoot are shortened about 15%. To investigate the robust capacity, we varied 
the system parameters from 10% to 20%, 30 %, 40% and 50%, and the results 
showed that the proposed method could tolerate upto 40% changes in model 
parameters. In addition, the robust deadbeat control scheme is easier to design and 
does not need any complicated mathmatical calculations except the normalisation of 
the coefficients table. 
 
Chapter 7 investigated the depth of anaesthesia control system using model 
predictive control technique. We applied a predictive control technique and 
developed a robust controller. The controller was designed based on a nominal 
patient model, and then tested for effectiveness on 12 patients’ parameters using 
Simulink. The MPC results were compared with that of a PID controller and with the 
internal model controller. The results showed that the proposed method reduced the 
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overshoot by about 20% compared to PID controller, reduced the settling time by 
about two minutes compared to the PID controller and about 10% compared to IMC 
controller (about one minute shorter) and that it was more robust to disturbances 
caused by parameter changes.  
 
These simulations and evaluations performed in this study provide a guarantee on 
feedback control of depth of anaesthesia. In addition, the patient profiles developed 
and used in the current study would be valuable in future studies on depth of 
anaesthesia control. 
 
Currently, the process of monitoring depth of anaesthesia and administration of a 
general anaesthetic during surgery is a closed-loop control system where the human 
is responsible for reasoning and action. Anaesthetists play the roles of controller and 
actuator by deciding on the amount of anaesthetic and when to administer it. On the 
other hand, the activity of monitoring is performed automatically by commercially 
available depth of anaesthesia monitors. Together they form a closed-loop control 
system. One of the main drawbacks in developing active drug delivery systems is the 
lack of accurate mathematical models for characterizing the dynamic behavior of 
drugs on physiological variables. System nonlinearities, model parameter variations 
from patient to patient, as  well  as  parameter variations within the same patient 
under different conditions make it very challenging to develop models and effective 
control law architectures for active drug delivery systems. Even though control 
strategies based on fixed-gain linear control laws, adaptive linear control laws, and 
rule-based (fuzzy logic) control laws have been proposed in the literature, the 
complex and highly uncertain nature of patient response to multiple drugs renders 
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such strategies deficient in the face of large system variations and system 
nonlinearities. 
 
This project is at the forefront of current international research, which addresses 
fundamental questions in the DoA assessment and control. The new models and 
control algorithms developed in this project is immediately useful in the development 
of new DoA control systems that have potential to greatly improve the comfort of 
patients, reduce the medical cost and avoid intraoperative awareness and all its 
consequences. 
8.3 Future Work 
A number of important topics on modeling and control of depth of anesthesia are 
outlined for further investigation in this project. 
 
The depth of anaesthesia control requires the construction of an accurate model to 
describe a more realistic surgical scenario and to include additional inputs and 
outputs. Anaesthesia control can be developed using non-linear controllers to 
improve the patient’s safety during surgery and rehabilitation after surgery. 
 
Construction of multi-drug strategies is necessary, because sole control of hypnosis 
or analgesia will not provide the anesthetists with the full benefits of automatization.  
 
This dissertation has emphasized the performance of several model-based predictive 
controllers for anesthesia regulation via simulations, but their clinical applicability 
and performance need to be established and demonstrated. For this reason, clinical 
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tests must be conducted before the developed control system can be used by the 
clinical team in the operating theatre. This important aspect must be investigated in 
detail in multi-disciplinary research studies. 
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